ClinicalTrials.gg
CompletedNCT00724867Updated Mar 28, 2016Results posted

A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States

A Phase 3 interventional study of Belimumab 1 mg/kg and Belimumab 10 mg/kg in Systemic Lupus Erythematosus, sponsored by Human Genome Sciences Inc., a GSK Company. Completed at 51 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-03-28.

Sponsored by Human Genome Sciences Inc., a GSK Company (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
268
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing belimumab in Lupus Erythematosus, Systemic — 4 open to participants now, 7 under way, none of them phase 3. belimumab · Lupus Erythematosus, Systemic.

Enrollment
12th of 36
268 · median 81
Started
2008
with 2 others
Phase 3
11 of 36
none open now
Registered
7th of 36
by date
Lead sponsor
7 of 36
Human Genome Sciences Inc., a GSK Company

Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, this one is the 12th largest by enrollment, is one of 3 that started in 2008, is one of 11 in phase 3, and was the 7th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

4 of the 36 studies testing belimumab in Lupus Erythematosus, Systemic are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About belimumab

belimumab: first FDA approval 2011 (BENLYSTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing belimumab in Lupus Erythematosus, Systemic, or all of them as a file.
02

Study summary

This is a continuation study to provide continuing treatment to subjects who completed study HGS1006-C1056 in the United States, to evaluate the long-term safety and efficacy of belimumab(LymphoStat-B™) in subjects with SLE disease.

Read the detailed description

This is a long-term continuation study to provide continuing treatment to subjects who completed study HGS1006-C1056 in the United States. This study is to evaluate the long-term safety and efficacy of belimumab (LymphoStat-B™) in subjects with SLE disease.

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • Systemic Lupus Erythematosus
  • Belimumab
  • SLE
  • Antibodies
  • Lupus
  • Autoimmune Diseases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have completed the HGS1006-C1056 protocol in the United States through Week 72 visit.
  • Be able to receive 1st dose of belimumab for HGS 1006-c1066 four weeks after last dose in HGS1006-c1056.

Exclusion criteria

Exclusion Criteria:

  • Have developed any other medical disease or condition that has made the subject unsuitable for this study in the opinion of their physician.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
268 participants (actual)

Study arms

  • Experimental
    Belimumab 1 mg/kg

    Belimumab 1 mg/kg IV every 28 days

    Biological: Belimumab 1 mg/kg

  • Experimental
    Belimumab 10 mg/kg

    Belimumab 10 mg/kg IV every 28 days

    Biological: Belimumab 10 mg/kg

Interventions

  • BiologicalBelimumab 1 mg/kg

    Drug page: Belimumab

    Belimumab 1 mg/kg IV over one hour every 28 days

    Also known as: BENLYSTA, HGS1006, LymphoStat-B™

  • BiologicalBelimumab 10 mg/kg

    Drug page: Belimumab

    Belimumab 10 mg/kg IV over one hour every 28 days

    Also known as: LymphoStat-B™, BENLYSTA, HGS1006

06

What researchers measure

Primary outcomes

  1. Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs)

    An AE is defined as any untoward medical occurrence in a participant (par.) temporally associated with the use of a investigational product (IP), whether or not considered related to the IP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of an IP. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is an important medical event that jeopardizes the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, or is associated with liver injury and impaired liver function. Only those participants available at the specified time points (represented by n=X, in the category titles) were analyzed.

    Time frame: Up to Week 440

  2. AE Rates by System Organ Class (SOC) During the Study

    AE rates by SOC adjusting for participant-years on study drug anytime post Baseline are summarized, which included the follow up visits. Only treatment-emergent adverse events (AEs) are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. The event rate of an AE was calculated as the number of events per 100 participant years: Event Rate = 100\* Number of Events / Participant Years. Participant years were calculated as sum across all participants (\[last visit of interval day - first visit of interval day + 1\]/365). Participant years excluded between study gaps if participant had not started extension study on date of last visit of parent study.

    Time frame: Up Week 440

  3. SAE Rates by System Organ Class (SOC) During the Study

    SAE rates by SOC adjusting for participants-years on study drug anytime post Baseline are summarized, which included the follow up visits. Only treatment-emergent SAEs are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. The event rate of an SAE was calculated as the number of events per 100 participant years: Event Rate = 100\* Number of Events / participants Years. participants years were calculated as = sum across all participants (\[last visit of interval day - first visit of interval day + 1\]/365). participants years excluded between study gaps if participant had not started extension study on date of last visit of parent study.

    Time frame: Up to Week 440

  4. Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points

    Hematology parameters were assessed at Baseline (BL) (Day 0), Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in APTT and PT is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

    Time frame: Up to Week 440

  5. Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Neutrophils Segmented and Platelets at the Indicated Time Points

    Hematology parameters were assessed at Baseline (BL) (Day 0), Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in basophils, eosinophils, lymphocytes, monocytes, neutrophils, neutrophils segmented and platelets is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

    Time frame: Up to Week 440

  6. Change From Baseline in Erythrocytes at the Indicated Time Points

    Hematology parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in erythrocytes is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

    Time frame: Up to Week 440

  7. Change From Baseline in Hematocrit at the Indicated Time Points

    Hematology parameters were assessed at Baseline (BL) (Day 0), Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in hematocrit is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

    Time frame: Up to Week 440

  8. Change From Baseline in Hemoglobin at the Indicated Time Points

    Hematology parameters were assessed at Baseline (BL) (Day 0), Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in hemoglobin is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

    Time frame: Up to Week 440

  9. Change From Baseline in Albumin and Protein at the Indicated Time Points

    Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in albumin and protein is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

    Time frame: Up to Week 440

  10. Change From Baseline in Blood Urea Nitrogen, Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points

    Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in blood urea nitrogen, glucose, calcium, carbon dioxide, chloride, magnesium, phosphate, potassium and sodium is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

    Time frame: Up to Week 440

  11. Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points

    Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in urate, creatinine and bilirubin is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

    Time frame: Up to Week 440

  12. Change From Baseline in Creatinine Clearance at the Indicated Time Points

    Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in creatinine clearance is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

    Time frame: Up to Week 440

  13. Change From Baseline in BUN/Creatinine at the Indicated Time Points

    Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in BUN/creatinine is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

    Time frame: Up to Week 440

  14. Change From Baseline in Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase and Lactate Dehydrogenase at the Indicated Time Points

    Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit. Change from Baseline in alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, gamma glutamyl transferase and lactate dehydrogenase is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

    Time frame: Up to Week 432

  15. Number of Participants With the Indicated Immunogenic Response

    Immunogenic response was assessed by binding confirmatory assay at Baseline (BL) (Day 0), at Week 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Number of participants with the indicated immunogenic response are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Results of binding confirmatory assay were categorized as negative, persistent positive (defined as a positive immunogenic response that occurs at least 2 consecutive assessments or a single result at the final assessment) or transient positive (defined as a single positive immunogenic response that does not occur at the final assessment). Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

    Time frame: Up to Week 440

  16. Systolic Blood Pressure and Diastolic Blood Pressure at Indicated Time Points.

    Systolic blood pressure (SBP) and diastolic blood pressure (DBP) was measured at Baseline (BL) (Day 0), at Week 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

    Time frame: Up to Week 432

  17. Percentage of Participants With at Least 25% Increase From Baseline in Creatinine at Indicated Time Points.

    Serum creatinine was assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Percentage of participants with at least 25% increase from baseline in creatinine are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

    Time frame: Up to Week 440

  18. Percentage of Participants With at Least 25% Reduction From Baseline in Creatinine at Indicated Time Points. Amongst Subjects With Abnormal (>124 Umol/L) Creatinine at Baseline by Year Interval.

    Serum creatinine was assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Percentage of participants with at least 25% reduction from baseline in creatinine are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

    Time frame: Up to Week 440

Secondary outcomes

  1. Number of Participants With Serum Immunoglobulins Below the Lower Limit of Normal at Indicated Time Points.

    Serum immunoglobulin G (IgG) was collected at Baseline (BL) (Day 0), at Week 24 and Week 48 in first year, at Week 48 in subsequent years up to 8 years and at follow-up (up to 8 weeks post last infusion). Number of participants with serum immunoglobulins below the lower limit of normal (LLN) (\<0.5 nanograms per milliliter \[ng/mL\]) are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

    Time frame: Up to Week 392

  2. Percentage of Participants Achieving SRI Response at Indicated Time Points

    The percentage of participants achieving a SLE Responder Index (SRI) response at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion) are summarized. The BL is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Response is defined as:\>=4 point reduction from the BL in the safety of estrogen in lupus national assessment (SELENA) SLE disease activity index (SLEDAI) score and no worsening (increase of \<0.30 points from the BL) in Physicians Global Assessment (PGA), and no new British Isles Lupus Assessment Group (BILAG) A organ domain score or 2 new BILAG B organ domain scores compared with the BL. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

    Time frame: Up to Week 440

  3. Observed Anti-double Stranded DNA Levels at Indicated Time Points.

    Anti-double stranded deoxyribonucleic acid (anti-dsDNA) levels were assessed at Baseline (BL) (Day 0), at Week 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks in participants who were positive at baseline (anti-dsDNA \>=30 International Units/milliliter \[IU/mL\]). Observed anti-dsDNA levels are summarized. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

    Time frame: Up to Week 432

  4. Median Percent Change From Baseline in Anti-double Stranded DNA at Indicated Time Points.

    Anti-dsDNA levels were assessed at Baseline (BL) (Day 0), 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit in participants who were positive at baseline (anti-dsDNA ≥30 IU/mL). Median percent change from Baseline in anti-dsDNA levels are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Percent change from Baseline is calculated as: 100 x (\[Post-Dose Visit Value - Baseline\] / Baseline). Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

    Time frame: Up to Week 432

  5. Observed Complement C3 and C4 Levels at Indicated Time Points

    Complement C3 and C4 levels were assessed at Baseline (BL) (Day 0), at Week 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at exit visit in participants with low complements at Baseline (C3 \<90 milligram per deciliter (mg/dL) and C4 \<16 mg/dL). Observed complement C3 and C4 levels are summarized. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

    Time frame: Up to Week 440

  6. Median Percent Change From Baseline in Complement C3 and C4 Levels at Indicated Time Points

    Complement C3 and C4 levels were assessed at Baseline (BL) (Day 0), 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit in participants with low complements at Baseline (C3 \<90 milligrams per decilitre (mg/dL) and C4 \<16 mg/dL). Median percent change from Baseline in complement C3 and C4 levels are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Percent change from Baseline is calculated as: 100 x (\[Post-Dose Visit Value - Baseline\] / Baseline). Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

    Time frame: Up to Week 432

  7. Percent of Participants With Daily Prednisone Dose Reduction at Indicated Time Points.

    Trends for reduction in prednisone use in participants receiving belimumab were observed up to 432 weeks. Percentage of participants with daily prednisone dose reduced to \<=7.5 mg/day from \>7.5 mg/kg at the Baseline are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

    Time frame: Up to Week 432

  8. Percent of Participants With >= 50% Reduction in Proteinuria at Indicated Time Points.

    Proteinuria is defined as the presence of an excess of serum proteins in the urine. Trends for reduction in proteinuria in participants receiving belimumab were assessed up to 432 weeks and at Exit visit. Percentage of participants with \>= 50% reduction in proteinuria among participants with Baseline proteinuria \>0.5 g/24 hour (hr) are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

    Time frame: Up to Week 432

  9. Observed B-cell Levels at Indicated Time Points.

    B-cell levels were assessed at Baseline (BL) (Day 0), Week (Wk) 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit. Observed absolute B cell subsets (CD20+), CD19+/27BRIGHT/38BRIGHT SLE subset, CD19+20-27hi+ short-lived plasma cells (SLPC), CD20+/138+ plasmacytoid, CD20+/27+ memory, CD20+/27- naïve, CD20+/69+activated, CD20-/138+ plasma cells, Total CD19+ B-cells (CD19+) levels are summarized. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

    Time frame: Up to Week 432

  10. Median Percent Change From Baseline in B Cell Levels at Indicated Time Points.

    B-cell levels were assessed at Baseline (BL) (Day 0), Week (Wk) 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit. Median percent change from Baseline in absolute B cell subsets (CD20+), CD19+/27BRIGHT/38BRIGHT SLE subset, CD19+20-27hi+ short-lived plasma cells (SLPC), CD20+/138+ plasmacytoid, CD20+/27+ memory, CD20+/27- naïve, CD20+/69+activated, CD20-/138+ plasma cells, Total CD19+ B-cells (CD19+) levels are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Percent change from Baseline is calculated as: 100 x (\[Post-Dose Visit Value - Baseline\] / Baseline). Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

    Time frame: Up to Week 432

  11. Percentage of Participants With Worsening in SLICC/ACR Damage Index at Indicated Time Points

    Systemic Lupus International Collaborative Clinics/American College of Rheumatology (SLICC/ACR) Damage Index is a tool used to assess non-reversible organ damage in SLE patients. Damage Index is used to assess 12 systems by 41 items. Score is given as 1 or sometimes 2, if occur more than once, so that that the maximum possible score is 47. Higher damage index scores early in disease are associated with a poor prognosis and with increased mortality. Damage index was assessed at BL (Day 0), Week 48 in first year, at Week 48 in subsequent years up to 8 years. Percentage of participants with worsening in damage index (change \>0) are summarized. The BL is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points were analyzed ( n=X).

    Time frame: Up to Week 384

  12. Change From Baseline in SF-36 Healthy Survey Overall Component Scores at Indicated Time Point

    The SF-36v2 is a participant-reported short form survey to measure functional health and well-being. There are 36 items grouped into eight health domains: Vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning and mental health. SF-36v2 gives a score (0-100) for each of these domains as well as summary score for the physical component score (PCS) and mental component score (MCS) based on the responses by participants. The lower the score the more disability and the higher the score the less disability. The BL is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from BL was calculated as the individual post-BL value minus the BL value. Only those participants available at the specified time points were analyzed ( n=X).

    Time frame: Up to Week 384

  13. Change From Baseline in SF-36 Healthy Survey Overall Component Scores at Indicated Timepoints

    The SF-36v2 is a participant-reported survey to measure functional health and well-being. There are 36 items grouped into eight health domains: Vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning and mental health. SF-36v2 gives a score (0-100) for each of these domains as well as summary score for the physical component score (PCS) and mental component score (MCS) based on the responses by participants. The lower the score the more disability and the higher the score the less disability. The BL is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from BL was calculated as the individual post-BL value minus the BL value. Only those participants available at the specified time points were analyzed ( n=X).

    Time frame: Up to Week 384

  14. Change From Baseline in FACIT-Fatigue Scale Total Score at Indicated Time Point

    The FACIT-F scale measures the severity and impact of fatigue on functioning and health related quality of life experienced in the past 7 days. FACIT-Fatigue scale total score was assessed at BL (Day 0), Wk 48 in first year, at Wk 48 in subsequent Yrs up to 8 Yrs.The level of fatigue is measured by 13 questions assessed on a four-point scale (0=not at all fatigued; 1=a little bit fatigued; 2=somewhat fatigued; 3=quite a bit fatigued; 4=very much fatigued; possible total score of 0 to 52). Change from BL in FACIT-Fatigue scale total score are summarized. The BL is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from BL was calculated as the individual post-BL value minus the BL value. A negative change from BL represents a worsening condition. Only those participants available at the specified time points were analyzed ( n=X).

    Time frame: Up to Week 384

  15. Percentage of Participants With Improvement in FACIT-Fatigue Scale Score Exceeding the MCID at Indicated Time Points

    The FACIT-F scale measures the severity and impact of fatigue on functioning and health related quality of life experienced in the past 7 days. FACIT-Fatigue scale total score was assessed at BL (Day 0), Week 48 in first year, at Week 48 in subsequent years up to 8 years. The level of fatigue is measured by 13 questions assessed on a four-point scale (0=not at all fatigued; 1=a little bit fatigued; 2=somewhat fatigued; 3=quite a bit fatigued; 4=very much fatigued; possible total score of 0 to 52). Percentage of participants with improvement in FACIT-Fatigue scale score exceeding the minimum clinically important difference (MCID) (\>=4 points) are summarized. Only those participants available at the specified time points were analyzed ( n=X).

    Time frame: Up to Week 384

07

Results

Posted Mar 28, 2016

Participant flow

Participant flow — Overall Study
MilestoneBelimumab 10 mg/kg IV
Started268
Completed140
Not completed128
Withdrew: Adverse event25
Withdrew: Lack of efficacy14
Withdrew: Lost to follow-up12
Withdrew: Non-compliance with study drug6
Withdrew: Physician decision17
Withdrew: Protocol violation1
Withdrew: Withdrawal by subject31
Withdrew: Sponsor decision to end study14
Withdrew: Subject incarcerated1
Withdrew: Developed withdrawal criteria- pregnancy4
Withdrew: Subject moved out of state1
Withdrew: Elected to exit due to site closure2

Outcome measures

PrimaryNumber of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs)

An AE is defined as any untoward medical occurrence in a participant (par.) temporally associated with the use of a investigational product (IP), whether or not considered related to the IP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of an IP. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is an important medical event that jeopardizes the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, or is associated with liver injury and impaired liver function. Only those participants available at the specified time points (represented by n=X, in the category titles) were analyzed.

Time frame:
Up to Week 440
Reported as:
Number · Participants
Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs)
ParticipantsBelimumab 10 mg/kg IV
AE, Any time post baseline, n=268267
AE, Year 0-1, n=268260
AE, Year 1-2, n=259235
AE, Year 2-3, n=244206
AE, Year 3-4, n=219184
AE, Year 4-5, n=202167
AE, Year 5-6, n=192145
AE, Year 6-7, n=13087
AE, Year 7 plus, n=6531
SAE, Any time post baseline, n=268112
SAE, Year 0-1, n=26833
SAE, Year 1-2, n=25930
SAE, Year 2-3, n=24425
SAE, Year 3-4, n=21922
SAE, Year 4-5, n=20224
SAE, Year 5-6, n=19216
SAE, Year 6-7, n=13013
SAE, Year 7 plus, n=653
PrimaryAE Rates by System Organ Class (SOC) During the Study

AE rates by SOC adjusting for participant-years on study drug anytime post Baseline are summarized, which included the follow up visits. Only treatment-emergent adverse events (AEs) are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. The event rate of an AE was calculated as the number of events per 100 participant years: Event Rate = 100\* Number of Events / Participant Years. Participant years were calculated as sum across all participants (\[last visit of interval day - first visit of interval day + 1\]/365). Participant years excluded between study gaps if participant had not started extension study on date of last visit of parent study.

Time frame:
Up Week 440
Reported as:
Number · Adverse events/100 participant-years
AE Rates by System Organ Class (SOC) During the Study
Adverse events/100 participant-yearsBelimumab 10 mg/kg IV
Infections and infestations134.4
Musculoskeletal and connective tissue disorders75.5
Gastrointestinal disorders53.6
Injury, poisoning and procedural complications32.3
Skin and subcutaneous tissue disorders30
Nervous system disorders29.7
Respiratory, thoracic and mediastinal disorders28.5
General disorders and administration sitecondition27.9
Psychiatric disorders12.4
Metabolism and nutrition disorders10.1
Vascular disorders9.1
Investigations9.1
Eye disorders8.2
Reproductive system and breast disorders6.7
Cardiac disorders6.4
Immune system disorders6
Renal and urinary disorders5.3
Neoplasms benign, malignant and unspecified5
Blood and lymphatic system disorders4.4
Ear and labyrinth disorders3.8
Hepatobiliary disorders2.3
Endocrine disorders1.8
Social circumstances0.8
Congenital, familial and genetic disorders0.5
Pregnancy, puerperium and perinatal conditions0.1
PrimarySAE Rates by System Organ Class (SOC) During the Study

SAE rates by SOC adjusting for participants-years on study drug anytime post Baseline are summarized, which included the follow up visits. Only treatment-emergent SAEs are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. The event rate of an SAE was calculated as the number of events per 100 participant years: Event Rate = 100\* Number of Events / participants Years. participants years were calculated as = sum across all participants (\[last visit of interval day - first visit of interval day + 1\]/365). participants years excluded between study gaps if participant had not started extension study on date of last visit of parent study.

Time frame:
Up to Week 440
Reported as:
Number · Adverse events/100 participant-years
SAE Rates by System Organ Class (SOC) During the Study
Adverse events/100 participant-yearsBelimumab 10 mg/kg IV
Infections and infestations4
Gastrointestinal disorders2.2
Musculoskeletal and connective tissue disorders2
General disorders and administration sitecondition1.7
Nervous system disorders1.4
Injury, poisoning and procedural complications1.4
Vascular disorders1
Neoplasms benign, malignant and unspecified1
Respiratory, thoracic and mediastinal disorders0.7
Cardiac disorders0.6
Metabolism and nutrition disorders0.6
Psychiatric disorders0.5
Renal and urinary disorders0.5
Hepatobiliary disorders0.4
Blood and lymphatic system disorders0.3
Reproductive system and breast disorders0.3
Immune system disorders0.1
Investigations0.1
Skin and subcutaneous tissue disorders0.1
Congenital, familial and genetic disorders0.1
Endocrine disorders0.1
Eye disorders0.1
Pregnancy, puerperium and perinatal conditions0.1
PrimaryChange From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points

Hematology parameters were assessed at Baseline (BL) (Day 0), Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in APTT and PT is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

Time frame:
Up to Week 440
Reported as:
Mean · Seconds
Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points
SecondsBelimumab 10 mg/kg IV
APTT, Year 1, Week 4, n= 821.3 ± 4.46
APTT, Year 1, Week 12, n= 791 ± 4.56
APTT, Year 1, Week 24, n= 2430.7 ± 4.81
APTT, Year 1, Week 36, n= 711.4 ± 4.83
APTT, Year 1, Week 48, n= 2461.7 ± 5.37
APTT, Year 2, Week 24, n= 2312.7 ± 5.88
APTT, Year 2, Week 48, n= 2203.9 ± 5.39
APTT, Year 3, Week 24, n= 2064.5 ± 4.92
APTT, Year 3, Week 48, n= 2024 ± 5.34
APTT, Year 4, Week 24, n= 2014.2 ± 6.51
APTT, Year 4, Week 48, n= 1854.7 ± 8.19
APTT, Year 5, Week 24, n= 1744.7 ± 7.03
APTT, Year 5, Week 48, n= 1713.6 ± 5.46
APTT, Year 6, Week 24, n= 1604.3 ± 6.37
APTT, Year 6, Week 48, n= 1264.8 ± 7.71
APTT, Year 7, Week 24, n= 1184.4 ± 4.77
APTT, Year 7, Week 48, n= 925 ± 9.55
APTT, Year 8, Week 24, n= 594.7 ± 5.02
APTT, Year 8, Week 48, n= 284.7 ± 5.51
APTT, Year 9, Week 24, n= 28.5 ± 13.44
APTT, Exit, n= 2303.1 ± 6.72
APTT, 8 Week, Follow-Up, n= 1043.3 ± 8.58
PT, Year 1, Week 4, n= 82-0.05 ± 1.463
PT, Year 1, Week 12, n= 79-0.66 ± 3.502
PT, Year 1, Week 24, n= 244-0.04 ± 3.239
PT, Year 1, Week 36, n= 71-0.42 ± 3.943
PT, Year 1, Week 48, n= 2460.2 ± 4.493
PT, Year 2, Week 24, n= 2330.52 ± 5.059
PT, Year 2, Week 48, n= 2210.24 ± 2.693
PT, Year 3, Week 24, n= 2060.26 ± 2.983
PT, Year 3, Week 48, n= 2020.34 ± 3.77
PT, Year 4, Week 24, n= 2010.39 ± 3.047
PT, Year 4, Week 48, n= 1861.96 ± 14.36
PT, Year 5, Week 24, n= 1740.6 ± 3.56
PT, Year 5, Week 48, n= 1720.5 ± 5.488
PT, Year 6, Week 24, n= 1600.39 ± 3.333
PT, Year 6, Week 48, n= 1260.55 ± 3.473
PT, Year 7, Week 24, n= 1180.72 ± 3.23
PT, Year 7, Week 48, n= 920.68 ± 5.149
PT, Year 8, Week 24, n= 580.5 ± 2.401
PT, Year 8, Week 48, n= 281.85 ± 4.759
PT, Year 9, Week 24, n= 21.45 ± 2.758
PT, Exit, n= 2290.57 ± 3.972
PT, 8 Week, Follow-Up, n= 1030.33 ± 2.202
PrimaryChange From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Neutrophils Segmented and Platelets at the Indicated Time Points

Hematology parameters were assessed at Baseline (BL) (Day 0), Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in basophils, eosinophils, lymphocytes, monocytes, neutrophils, neutrophils segmented and platelets is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

Time frame:
Up to Week 440
Reported as:
Mean · Billion cells per liter
Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Neutrophils Segmented and Platelets at the Indicated Time Points
Billion cells per literBelimumab 10 mg/kg IV
Basophils, Year 1, Week 4, n= 2570.001 ± 0.0157
Basophils, Year 1, Week 12, n= 2490.002 ± 0.0173
Basophils, Year 1, Week 24, n= 2490.003 ± 0.0175
Basophils, Year 1, Week 36, n= 2400.003 ± 0.0172
Basophils, Year 1, Week 48, n= 2540.001 ± 0.016
Basophils, Year 2, Week 24, n= 2500.002 ± 0.0159
Basophils, Year 2, Week 48, n= 2330.001 ± 0.0157
Basophils, Year 3, Week 24, n= 2190.004 ± 0.0156
Basophils, Year 3, Week 48, n= 2110.004 ± 0.0179
Basophils, Year 4, Week 24, n= 2100.004 ± 0.0157
Basophils, Year 4, Week 48, n= 1940.002 ± 0.0159
Basophils, Year 5, Week 24, n= 1880.003 ± 0.0168
Basophils, Year 5, Week 48, n= 1840.005 ± 0.0226
Basophils, Year 6, Week 24, n= 1760.003 ± 0.0149
Basophils, Year 6, Week 48, n= 1320.003 ± 0.0178
Basophils, Year 7, Week 24, n= 1220.005 ± 0.0189
Basophils, Year 7, Week 48, n= 960.009 ± 0.0188
Basophils, Year 8, Week 24, n= 600.002 ± 0.0155
Basophils, Year 8, Week 48, n= 290.002 ± 0.0147
Basophils, Year 9, Week 24, n= 20.02 ± 0.0141
Basophils, Exit, n= 2330.005 ± 0.0183
Basophils, 8 Week, Follow-Up, n= 1060.004 ± 0.0186
Eosinophils, Year 1, Week 4, n= 257-0.001 ± 0.0893
Eosinophils, Year 1, Week 12, n= 2490.005 ± 0.1089
Eosinophils, Year 1, Week 24, n= 2490.008 ± 0.1281
Eosinophils, Year 1, Week 36, n= 2400.004 ± 0.1279
Eosinophils, Year 1, Week 48, n= 2540.007 ± 0.1216
Eosinophils, Year 2, Week 24, n= 2500.006 ± 0.1228
Eosinophils, Year 2, Week 48, n= 233-0.009 ± 0.1234
Eosinophils, Year 3, Week 24, n= 219-0.002 ± 0.1303
Eosinophils, Year 3, Week 48, n= 211-0.023 ± 0.1276
Eosinophils, Year 4, Week 24, n= 210-0.034 ± 0.125
Eosinophils, Year 4, Week 48, n= 194-0.032 ± 0.1407
Eosinophils, Year 5, Week 24, n= 188-0.038 ± 0.1281
Eosinophils, Year 5, Week 48, n= 184-0.019 ± 0.1547
Eosinophils, Year 6, Week 24, n= 176-0.027 ± 0.1169
Eosinophils, Year 6, Week 48, n= 132-0.038 ± 0.1227
Eosinophils, Year 7, Week 24, n= 122-0.017 ± 0.1269
Eosinophils, Year 7, Week 48, n= 96-0.026 ± 0.1401
Eosinophils, Year 8, Week 24, n= 60-0.031 ± 0.1425
Eosinophils, Year 8, Week 48, n= 29-0.032 ± 0.1121
Eosinophils, Year 9, Week 24, n= 2-0.08 ± 0.0141
Eosinophils, Exit, n= 233-0.026 ± 0.1295
Eosinophils, 8 Week, Follow-Up, n= 106-0.022 ± 0.1401
Leukocytes, Year 1, Week 4, n= 2570.08 ± 1.642
Leukocytes, Year 1, Week 12, n= 2490.18 ± 1.856
Leukocytes, Year 1, Week 24, n= 249-0.02 ± 1.884
Leukocytes, Year 1, Week 36, n= 2400.04 ± 2.092
Leukocytes, Year 1, Week 48, n= 254-0.01 ± 1.863
Leukocytes, Year 2, Week 24, n= 250-0.19 ± 2.087
Leukocytes, Year 2, Week 48, n= 233-0.27 ± 2.19
Leukocytes, Year 3, Week 24, n= 219-0.33 ± 1.959
Leukocytes, Year 3, Week 48, n= 211-0.42 ± 1.876
Leukocytes, Year 4, Week 24, n= 210-0.29 ± 2.205
Leukocytes, Year 4, Week 48, n= 194-0.35 ± 2.207
Leukocytes, Year 5, Week 24, n= 188-0.4 ± 2.112
Leukocytes, Year 5, Week 48, n= 184-0.18 ± 2.389
Leukocytes, Year 6, Week 24, n= 176-0.4 ± 2.161
Leukocytes, Year 6, Week 48, n= 132-0.24 ± 2.164
Leukocytes, Year 7, Week 24, n= 122-0.22 ± 2.149
Leukocytes, Year 7, Week 48, n= 960.05 ± 2.388
Leukocytes, Year 8, Week 24, n= 600.17 ± 2.297
Leukocytes, Year 8, Week 48, n= 29-0.63 ± 2.549
Leukocytes, Year 9, Week 24, n= 2-3.7 ± 1.273
Leukocytes, Exit, n= 2330.09 ± 2.969
Leukocytes, 8 Week, Follow-Up, n= 106-0.11 ± 2.613
Lymphocytes, Year 1, Week 4, n= 2570.076 ± 0.4223
Lymphocytes, Year 1, Week 12, n= 2490.039 ± 0.558
Lymphocytes, Year 1, Week 24, n= 2490.002 ± 0.5023
Lymphocytes, Year 1, Week 36, n= 2400.059 ± 0.5002
Lymphocytes, Year 1, Week 48, n= 254-0.02 ± 0.5129
Lymphocytes, Year 2, Week 24, n= 250-0.073 ± 0.5033
Lymphocytes, Year 2, Week 48, n= 233-0.036 ± 0.5299
Lymphocytes, Year 3, Week 24, n= 2190.002 ± 0.5621
Lymphocytes, Year 3, Week 48, n= 211-0.028 ± 0.572
Lymphocytes, Year 4, Week 24, n= 210-0.036 ± 0.5809
Lymphocytes, Year 4, Week 48, n= 194-0.067 ± 0.5678
Lymphocytes, Year 5, Week 24, n= 188-0.07 ± 0.5924
Lymphocytes, Year 5, Week 48, n= 184-0.047 ± 0.629
Lymphocytes, Year 6, Week 24, n= 176-0.021 ± 0.5876
Lymphocytes, Year 6, Week 48, n= 132-0.008 ± 0.5564
Lymphocytes, Year 7, Week 24, n= 1220.011 ± 0.6439
Lymphocytes, Year 7, Week 48, n= 960.143 ± 0.6619
Lymphocytes, Year 8, Week 24, n= 600.126 ± 0.6291
Lymphocytes, Year 8, Week 48, n= 290.059 ± 0.8495
Lymphocytes, Year 9, Week 24, n= 20.765 ± 1.4354
Lymphocytes, Exit, n= 233-0.025 ± 0.6129
Lymphocytes, 8 Week, Follow-Up, n= 1060.029 ± 0.6256
Monocytes, Year 1, Week 4, n= 2570.028 ± 0.1673
Monocytes, Year 1, Week 12, n= 2490.036 ± 0.1694
Monocytes, Year 1, Week 24, n= 2490.024 ± 0.1678
Monocytes, Year 1, Week 36, n= 2400.054 ± 0.1806
Monocytes, Year 1, Week 48, n= 2540.044 ± 0.1754
Monocytes, Year 2, Week 24, n= 2500.053 ± 0.1809
Monocytes, Year 2, Week 48, n= 2330.052 ± 0.1805
Monocytes, Year 3, Week 24, n= 2190.059 ± 0.1809
Monocytes, Year 3, Week 48, n= 2110.071 ± 0.1903
Monocytes, Year 4, Week 24, n= 2100.065 ± 0.1875
Monocytes, Year 4, Week 48, n= 1940.084 ± 0.1782
Monocytes, Year 5, Week 24, n= 1880.095 ± 0.1878
Monocytes, Year 5, Week 48, n= 1840.086 ± 0.1983
Monocytes, Year 6, Week 24, n= 1760.072 ± 0.1826
Monocytes, Year 6, Week 48, n= 1320.049 ± 0.1808
Monocytes, Year 7, Week 24, n= 1220.098 ± 0.1996
Monocytes, Year 7, Week 48, n= 960.097 ± 0.2032
Monocytes, Year 8, Week 24, n= 600.101 ± 0.1909
Monocytes, Year 8, Week 48, n= 290.024 ± 0.2074
Monocytes, Year 9, Week 24, n= 20.03 ± 0.3818
Monocytes, Exit, n= 2330.075 ± 0.1846
Monocytes, 8 Week, Follow-Up, n= 1060.093 ± 0.1958
Neutrophils, Year 1, Week 4, n= 257-0.027 ± 1.6734
Neutrophils, Year 1, Week 12, n= 2490.1 ± 1.7293
Neutrophils, Year 1, Week 24, n= 249-0.059 ± 1.8685
Neutrophils, Year 1, Week 36, n= 240-0.086 ± 2.1086
Neutrophils, Year 1, Week 48, n= 254-0.037 ± 1.7955
Neutrophils, Year 2, Week 24, n= 250-0.176 ± 2.0209
Neutrophils, Year 2, Week 48, n= 233-0.283 ± 2.1226
Neutrophils, Year 3, Week 24, n= 219-0.397 ± 1.8521
Neutrophils, Year 3, Week 48, n= 211-0.443 ± 1.763
Neutrophils, Year 4, Week 24, n= 210-0.288 ± 2.1214
Neutrophils, Year 4, Week 48, n= 194-0.342 ± 2.1425
Neutrophils, Year 5, Week 24, n= 188-0.392 ± 1.9654
Neutrophils, Year 5, Week 48, n= 184-0.207 ± 2.2312
Neutrophils, Year 6, Week 24, n= 176-0.424 ± 2.0787
Neutrophils, Year 6, Week 48, n= 132-0.251 ± 2.1415
Neutrophils, Year 7, Week 24, n= 122-0.315 ± 2.1382
Neutrophils, Year 7, Week 48, n= 96-0.176 ± 2.3755
Neutrophils, Year 8, Week 24, n= 60-0.025 ± 2.2303
Neutrophils, Year 8, Week 48, n= 29-0.681 ± 2.4214
Neutrophils, Year 9, Week 24, n= 2-4.44 ± 0.5798
Neutrophils, Exit, n= 2330.058 ± 2.9836
Neutrophils, 8 Week, Follow-Up, n= 106-0.214 ± 2.5793
Neutrophils segmented, Year 1, Week 4, n= 257-0.028 ± 1.6685
Neutrophils segmented, Year 1, Week 12, n= 2490.098 ± 1.7212
Neutrophils segmented, Year 1, Week 24, n= 249-0.059 ± 1.8683
Neutrophils segmented, Year 1, Week 36, n= 240-0.086 ± 2.1097
Neutrophils segmented, Year 1, Week 48, n= 254-0.044 ± 1.8014
Neutrophils segmented, Year 2, Week 24, n= 250-0.177 ± 2.0163
Neutrophils segmented, Year 2, Week 48, n= 233-0.284 ± 2.1204
Neutrophils segmented, Year 3, Week 24, n= 219-0.397 ± 1.8509
Neutrophils segmented, Year 3, Week 48, n= 211-0.444 ± 1.7607
Neutrophils segmented, Year 4, Week 24, n= 210-0.286 ± 2.1249
Neutrophils segmented, Year 4, Week 48, n= 194-0.342 ± 2.1464
Neutrophils segmented, Year 5, Week 24, n= 188-0.39 ± 1.9703
Neutrophils segmented, Year 5, Week 48, n= 184-0.207 ± 2.2273
Neutrophils segmented, Year 6, Week 24, n= 176-0.422 ± 2.0826
Neutrophils segmented, Year 6, Week 48, n= 132-0.249 ± 2.1432
Neutrophils segmented, Year 7, Week 24, n= 122-0.313 ± 2.1378
Neutrophils segmented, Year 7, Week 48, n= 96-0.179 ± 2.3698
Neutrophils segmented, Year 8, Week 24, n= 60-0.025 ± 2.2303
Neutrophils segmented, Year 8, Week 48, n= 29-0.681 ± 2.4214
Neutrophils segmented, Year 9, Week 24, n= 2-4.44 ± 0.5798
Neutrophils segmented, Exit, n= 2330.046 ± 2.8796
Neutrophils segmented, 8 Week, Follow-Up, n= 106-0.215 ± 2.5788
Platelets, Year 1, Week 4, n= 2542.9 ± 35.71
Platelets, Year 1, Week 12, n= 248-1.1 ± 42.04
Platelets, Year 1, Week 24, n= 247-2 ± 41.13
Platelets, Year 1, Week 36, n= 238-5.9 ± 46.11
Platelets, Year 1, Week 48, n= 252-8.4 ± 46.36
Platelets, Year 2, Week 24, n= 249-17.5 ± 56.18
Platelets, Year 2, Week 48, n= 233-18.8 ± 56.8
Platelets, Year 3, Week 24, n= 218-17 ± 56.86
Platelets, Year 3, Week 48, n= 210-22.4 ± 57.11
Platelets, Year 4, Week 24, n= 210-14.6 ± 64.11
Platelets, Year 4, Week 48, n= 193-17 ± 60.26
Platelets, Year 5, Week 24, n= 188-19 ± 65.99
Platelets, Year 5, Week 48, n= 184-17.6 ± 65.69
Platelets, Year 6, Week 24, n= 175-18.9 ± 62.88
Platelets, Year 6, Week 48, n= 132-23.7 ± 67.73
Platelets, Year 7, Week 24, n= 121-14 ± 77.75
Platelets, Year 7, Week 48, n= 96-24.7 ± 64.56
Platelets, Year 8, Week 24, n= 60-30.5 ± 65.89
Platelets, Year 8, Week 48, n= 29-40.7 ± 62.84
Platelets, Year 9, Week 24, n= 237 ± 83.44
Platelets, Exit, n= 233-9.4 ± 59.82
Platelets, 8 Week, Follow-Up, n= 106-8 ± 70.29
PrimaryChange From Baseline in Erythrocytes at the Indicated Time Points

Hematology parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in erythrocytes is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

Time frame:
Up to Week 440
Reported as:
Mean · Trillions cells per liter
Change From Baseline in Erythrocytes at the Indicated Time Points
Trillions cells per literBelimumab 10 mg/kg IV
Erythrocytes, Year 1, Week 4, n= 2570 ± 0.243
Erythrocytes, Year 1, Week 12, n= 2490.01 ± 0.284
Erythrocytes, Year 1, Week 24, n= 2500.04 ± 0.291
Erythrocytes, Year 1, Week 36, n= 2400.03 ± 0.309
Erythrocytes, Year 1, Week 48, n= 2540.06 ± 0.337
Erythrocytes, Year 2, Week 24, n= 2490.06 ± 0.341
Erythrocytes, Year 2, Week 48, n= 2330.04 ± 0.338
Erythrocytes, Year 3, Week 24, n= 2190.06 ± 0.361
Erythrocytes, Year 3, Week 48, n= 2110.04 ± 0.362
Erythrocytes, Year 4, Week 24, n= 2100.03 ± 0.37
Erythrocytes, Year 4, Week 48, n= 1940.07 ± 0.376
Erythrocytes, Year 5, Week 24, n= 1890.08 ± 0.395
Erythrocytes, Year 5, Week 48, n= 1840.1 ± 0.412
Erythrocytes, Year 6, Week 24, n= 1760.13 ± 0.405
Erythrocytes, Year 6, Week 48, n= 1320.19 ± 0.393
Erythrocytes, Year 7, Week 24, n= 1220.2 ± 0.438
Erythrocytes, Year 7, Week 48, n= 960.19 ± 0.441
Erythrocytes, Year 8, Week 24, n= 600.25 ± 0.404
Erythrocytes, Year 8, Week 48, n= 290.39 ± 0.403
Erythrocytes, Year 9, Week 24, n= 20.1 ± 0
Erythrocytes, Exit, n= 2330.26 ± 0.398
Erythrocytes, 8 Week, Follow-Up, n= 1060.2 ± 0.415
PrimaryChange From Baseline in Hematocrit at the Indicated Time Points

Hematology parameters were assessed at Baseline (BL) (Day 0), Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in hematocrit is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

Time frame:
Up to Week 440
Reported as:
Mean · Percentage
Change From Baseline in Hematocrit at the Indicated Time Points
PercentageBelimumab 10 mg/kg IV
Hematocrit, Year 1, Week 4, n= 2570.16 ± 2.247
Hematocrit, Year 1, Week 12, n= 2490.11 ± 2.62
Hematocrit, Year 1, Week 24, n= 2500.31 ± 2.683
Hematocrit, Year 1, Week 36, n= 2400.2 ± 2.836
Hematocrit, Year 1, Week 48, n= 2540.73 ± 3.087
Hematocrit, Year 2, Week 24, n= 2490.81 ± 3.321
Hematocrit, Year 2, Week 48, n= 2331.09 ± 3.433
Hematocrit, Year 3, Week 24, n= 2191.4 ± 3.604
Hematocrit, Year 3, Week 48, n= 2111.53 ± 3.545
Hematocrit, Year 4, Week 24, n= 2101.39 ± 3.448
Hematocrit, Year 4, Week 48, n= 1941.67 ± 3.414
Hematocrit, Year 5, Week 24, n= 1891.78 ± 3.596
Hematocrit, Year 5, Week 48, n= 1841.98 ± 3.943
Hematocrit, Year 6, Week 24, n= 1762.16 ± 3.94
Hematocrit, Year 6, Week 48, n= 1322.49 ± 3.561
Hematocrit, Year 7, Week 24, n= 1222.34 ± 4.166
Hematocrit, Year 7, Week 48, n= 961.86 ± 4.108
Hematocrit, Year 8, Week 24, n= 602.68 ± 3.807
Hematocrit, Year 8, Week 48, n= 293.49 ± 3.554
Hematocrit, Year 9, Week 24, n= 20.7 ± 0.99
Hematocrit, Exit, n= 2333.25 ± 3.613
Hematocrit, 8 Week, Follow-Up, n= 1063.04 ± 3.478
PrimaryChange From Baseline in Hemoglobin at the Indicated Time Points

Hematology parameters were assessed at Baseline (BL) (Day 0), Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in hemoglobin is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

Time frame:
Up to Week 440
Reported as:
Mean · Grams per liter
Change From Baseline in Hemoglobin at the Indicated Time Points
Grams per literBelimumab 10 mg/kg IV
Hemoglobin, Year 1, Week 4, n= 2570 ± 7.03
Hemoglobin, Year 1, Week 12, n= 2490.3 ± 8.17
Hemoglobin, Year 1, Week 24, n= 2500.5 ± 8.81
Hemoglobin, Year 1, Week 36, n= 2400.5 ± 9.51
Hemoglobin, Year 1, Week 48, n= 2542.1 ± 10.2
Hemoglobin, Year 2, Week 24, n= 2502.5 ± 11.07
Hemoglobin, Year 2, Week 48, n= 2332.4 ± 11.76
Hemoglobin, Year 3, Week 24, n= 2193.7 ± 11.93
Hemoglobin, Year 3, Week 48, n= 2113.9 ± 11.86
Hemoglobin, Year 4, Week 24, n= 2102.5 ± 11.91
Hemoglobin, Year 4, Week 48, n= 1943.2 ± 11.82
Hemoglobin, Year 5, Week 24, n= 1893.7 ± 12.44
Hemoglobin, Year 5, Week 48, n= 1843.7 ± 13.71
Hemoglobin, Year 6, Week 24, n= 1763.7 ± 13.6
Hemoglobin, Year 6, Week 48, n= 1324.2 ± 13.13
Hemoglobin, Year 7, Week 24, n= 1223.3 ± 14.73
Hemoglobin, Year 7, Week 48, n= 962.6 ± 14.98
Hemoglobin, Year 8, Week 24, n= 605.2 ± 12.78
Hemoglobin, Year 8, Week 48, n= 298.4 ± 12.98
Hemoglobin, Year 9, Week 24, n= 2-3 ± 2.83
Hemoglobin, Exit, n= 2337.2 ± 12.46
Hemoglobin, 8 Week, Follow-Up, n= 1066.5 ± 11.93
PrimaryChange From Baseline in Albumin and Protein at the Indicated Time Points

Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in albumin and protein is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

Time frame:
Up to Week 440
Reported as:
Mean · Grams per liter
Change From Baseline in Albumin and Protein at the Indicated Time Points
Grams per literBelimumab 10 mg/kg IV
Albumin, Year 1, Week 4, n= 251-0.3 ± 2.17
Albumin, Year 1, Week 12, n= 2480.1 ± 2.53
Albumin, Year 1, Week 24, n= 2460.3 ± 2.47
Albumin, Year 1, Week 36, n= 2380.4 ± 2.69
Albumin, Year 1, Week 48, n= 2501.1 ± 2.88
Albumin, Year 2, Week 24, n= 2481.1 ± 3.18
Albumin, Year 2, Week 48, n= 2331.2 ± 3.25
Albumin, Year 3, Week 24, n= 2181.3 ± 3.41
Albumin, Year 3, Week 48, n= 2091.4 ± 3.65
Albumin, Year 4, Week 24, n= 2071.3 ± 3.6
Albumin, Year 4, Week 48, n= 1941.5 ± 3.5
Albumin, Year 5, Week 24, n= 1841.7 ± 3.76
Albumin, Year 5, Week 48, n= 1782 ± 3.69
Albumin, Year 6, Week 24, n= 1751.8 ± 4.05
Albumin, Year 6, Week 48, n= 1341.8 ± 4.09
Albumin, Year 7, Week 24, n= 1231.4 ± 4.14
Albumin, Year 7, Week 48, n= 971.6 ± 4.19
Albumin, Year 8, Week 24, n= 602 ± 4.4
Albumin, Year 8, Week 48, n= 282.9 ± 3.92
Albumin, Year 9, Week 24, n= 21 ± 0
Albumin, Exit, n= 2352.2 ± 3.59
Albumin, 8 Week, Follow-Up, n= 1071.8 ± 3.77
Protein, Year 1, Week 4, n= 251-1.3 ± 3.73
Protein, Year 1, Week 12, n= 248-1.9 ± 4.41
Protein, Year 1, Week 24, n= 246-2.1 ± 4.31
Protein, Year 1, Week 36, n= 238-2.6 ± 4.59
Protein, Year 1, Week 48, n= 250-1.8 ± 4.91
Protein, Year 2, Week 24, n= 248-2.2 ± 4.9
Protein, Year 2, Week 48, n= 233-2.6 ± 5.08
Protein, Year 3, Week 24, n= 218-2.6 ± 5
Protein, Year 3, Week 48, n= 209-3 ± 5.36
Protein, Year 4, Week 24, n= 207-3.4 ± 5.3
Protein, Year 4, Week 48, n= 194-3.6 ± 5.22
Protein, Year 5, Week 24, n= 184-3.4 ± 5.44
Protein, Year 5, Week 48, n= 178-3.4 ± 5.16
Protein, Year 6, Week 24, n= 175-4 ± 5.55
Protein, Year 6, Week 48, n= 134-3.5 ± 5.81
Protein, Year 7, Week 24, n= 123-4.3 ± 5.56
Protein, Year 7, Week 48, n= 97-4.3 ± 5.87
Protein, Year 8, Week 24, n= 60-4.1 ± 5.78
Protein, Year 8, Week 48, n= 28-3 ± 5.18
Protein, Year 9, Week 24, n= 2-1.5 ± 2.12
Protein, Exit, n= 235-2.6 ± 5.53
Protein, 8 Week, Follow-Up, n= 107-3.1 ± 6.19
PrimaryChange From Baseline in Blood Urea Nitrogen, Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points

Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in blood urea nitrogen, glucose, calcium, carbon dioxide, chloride, magnesium, phosphate, potassium and sodium is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

Time frame:
Up to Week 440
Reported as:
Mean · Millimoles per liter
Change From Baseline in Blood Urea Nitrogen, Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points
Millimoles per literBelimumab 10 mg/kg IV
Blood urea nitrogen, Year 1, Week 4, n= 2510.026 ± 1.4283
Blood urea nitrogen, Year 1, Week 12, n= 248-0.1695 ± 1.4782
Blood urea nitrogen, Year 1, Week 24, n= 246-0.1612 ± 1.9011
Blood urea nitrogen, Year 1, Week 36, n= 238-0.1732 ± 1.5648
Blood urea nitrogen, Year 1, Week 48, n= 250-0.1013 ± 1.5557
Blood urea nitrogen, Year 2, Week 24, n= 248-0.1873 ± 1.6796
Blood urea nitrogen, Year 2, Week 48, n= 233-0.0134 ± 1.7024
Blood urea nitrogen, Year 3, Week 24, n= 218-0.0552 ± 1.7117
Blood urea nitrogen, Year 3, Week 48, n= 209-0.0472 ± 1.6693
Blood urea nitrogen, Year 4, Week 24, n= 207-0.09 ± 1.6775
Blood urea nitrogen, Year 4, Week 48, n= 194-0.1162 ± 1.721
Blood urea nitrogen, Year 5, Week 24, n= 184-0.0331 ± 1.6526
Blood urea nitrogen, Year 5, Week 48, n= 1780.0176 ± 1.7712
Blood urea nitrogen, Year 6, Week 24, n= 175-0.0029 ± 1.6054
Blood urea nitrogen, Year 6, Week 48, n= 134-0.0858 ± 1.6972
Blood urea nitrogen, Year 7, Week 24, n= 1230.0246 ± 1.6668
Blood urea nitrogen, Year 7, Week 48, n= 97-0.008 ± 1.6683
Blood urea nitrogen, Year 8, Week 24, n= 60-0.1152 ± 1.5362
Blood urea nitrogen, Year 8, Week 48, n= 28-0.1603 ± 1.5417
Blood urea nitrogen, Year 9, Week 24, n= 2-0.1805 ± 1.06
Blood urea nitrogen, Exit, n= 2350.0501 ± 1.7369
Blood urea nitrogen, 8 Week, Follow-Up, n= 1070.3248 ± 2.2109
Glucose, Year 1, Week 4, n= 2510.1088 ± 1.1734
Glucose, Year 1, Week 12, n= 2480.2006 ± 1.1712
Glucose, Year 1, Week 24, n= 2460.0881 ± 1.2279
Glucose, Year 1, Week 36, n= 2380.2158 ± 1.2519
Glucose, Year 1, Week 48, n= 2500.1482 ± 1.5029
Glucose, Year 2, Week 24, n= 2480.1146 ± 1.3072
Glucose, Year 2, Week 48, n= 2330.323 ± 1.5426
Glucose, Year 3, Week 24, n= 2180.1927 ± 1.4319
Glucose, Year 3, Week 48, n= 2090.1719 ± 1.4829
Glucose, Year 4, Week 24, n= 2070.2737 ± 1.6169
Glucose, Year 4, Week 48, n= 1940.2523 ± 2.1698
Glucose, Year 5, Week 24, n= 1840.2579 ± 1.4792
Glucose, Year 5, Week 48, n= 1780.2964 ± 1.7205
Glucose, Year 6, Week 24, n= 1750.2903 ± 1.7746
Glucose, Year 6, Week 48, n= 1340.3897 ± 1.7503
Glucose, Year 7, Week 24, n= 1230.297 ± 2.257
Glucose, Year 7, Week 48, n= 970.5098 ± 1.8839
Glucose, Year 8, Week 24, n= 600.449 ± 1.9609
Glucose, Year 8, Week 48, n= 280.7571 ± 2.2408
Glucose, Year 9, Week 24, n= 20.8845 ± 0.4094
Glucose, Exit, n= 2350.2986 ± 1.3871
Glucose, 8 Week, Follow-Up, n= 1070.3354 ± 1.4114
Calcium, Year 1, Week 4, n= 2420.0071 ± 0.0888
Calcium, Year 1, Week 12, n= 247-0.0043 ± 0.0872
Calcium, Year 1, Week 24, n= 244-0.0023 ± 0.0889
Calcium, Year 1, Week 36, n= 235-0.0156 ± 0.0884
Calcium, Year 1, Week 48, n= 2500.0007 ± 0.0896
Calcium, Year 2, Week 24, n= 246-0.0017 ± 0.0946
Calcium, Year 2, Week 48, n= 231-0.0019 ± 0.0922
Calcium, Year 3, Week 24, n= 214-0.0009 ± 0.09
Calcium, Year 3, Week 48, n= 205-0.0109 ± 0.1004
Calcium, Year 4, Week 24, n= 204-0.0115 ± 0.095
Calcium, Year 4, Week 48, n= 191-0.0072 ± 0.0889
Calcium, Year 5, Week 24, n= 184-0.0181 ± 0.0986
Calcium, Year 5, Week 48, n= 176-0.0011 ± 0.0912
Calcium, Year 6, Week 24, n= 172-0.0107 ± 0.0977
Calcium, Year 6, Week 48, n= 1340.0007 ± 0.0925
Calcium, Year 7, Week 24, n= 1210.0014 ± 0.0873
Calcium, Year 7, Week 48, n= 970.0063 ± 0.0964
Calcium, Year 8, Week 24, n= 60-0.0123 ± 0.0788
Calcium, Year 8, Week 48, n= 280.0021 ± 0.0935
Calcium, Year 9, Week 24, n= 2-0.005 ± 0.0354
Calcium, Exit, n= 2350.0151 ± 0.0923
Calcium, 8 Week, Follow-Up, n= 1070.0046 ± 0.1029
Carbon dioxide, Year 1, Week 4, n= 243-0.2 ± 2.72
Carbon dioxide, Year 1, Week 12, n= 245-0.4 ± 2.62
Carbon dioxide, Year 1, Week 24, n= 244-0.2 ± 2.51
Carbon dioxide, Year 1, Week 36, n= 234-0.1 ± 2.67
Carbon dioxide, Year 1, Week 48, n= 250-0.2 ± 2.64
Carbon dioxide, Year 2, Week 24, n= 2460 ± 2.58
Carbon dioxide, Year 2, Week 48, n= 231-0.5 ± 2.78
Carbon dioxide, Year 3, Week 24, n= 215-0.5 ± 2.75
Carbon dioxide, Year 3, Week 48, n= 205-0.9 ± 2.82
Carbon dioxide, Year 4, Week 24, n= 204-0.6 ± 2.7
Carbon dioxide, Year 4, Week 48, n= 191-0.6 ± 2.79
Carbon dioxide, Year 5, Week 24, n= 184-0.9 ± 2.68
Carbon dioxide, Year 5, Week 48, n= 176-0.7 ± 2.73
Carbon dioxide, Year 6, Week 24, n= 172-0.8 ± 2.62
Carbon dioxide, Year 6, Week 48, n= 134-0.7 ± 3.23
Carbon dioxide, Year 7, Week 24, n= 121-0.7 ± 2.84
Carbon dioxide, Year 7, Week 48, n= 97-0.3 ± 3.14
Carbon dioxide, Year 8, Week 24, n= 60-0.5 ± 3.17
Carbon dioxide, Year 8, Week 48, n= 28-0.7 ± 2.87
Carbon dioxide, Year 9, Week 24, n= 2-1 ± 1.41
Carbon dioxide, Exit, n= 2350.1 ± 2.74
Carbon dioxide, 8 Week, Follow-Up, n= 1070 ± 2.55
Chloride, Year 1, Week 4, n= 2510.2 ± 2.8
Chloride, Year 1, Week 12, n= 2480.1 ± 2.53
Chloride, Year 1, Week 24, n= 2460.3 ± 2.31
Chloride, Year 1, Week 36, n= 2380.5 ± 2.43
Chloride, Year 1, Week 48, n= 2500 ± 2.53
Chloride, Year 2, Week 24, n= 2480.1 ± 2.6
Chloride, Year 2, Week 48, n= 2330.1 ± 3.03
Chloride, Year 3, Week 24, n= 218-0.1 ± 3.01
Chloride, Year 3, Week 48, n= 2090.1 ± 3.06
Chloride, Year 4, Week 24, n= 207-0.4 ± 3.28
Chloride, Year 4, Week 48, n= 194-0.3 ± 2.83
Chloride, Year 5, Week 24, n= 184-0.3 ± 3.06
Chloride, Year 5, Week 48, n= 178-0.1 ± 3.02
Chloride, Year 6, Week 24, n= 1750 ± 3.11
Chloride, Year 6, Week 48, n= 1340.3 ± 2.89
Chloride, Year 7, Week 24, n= 1230.4 ± 3.1
Chloride, Year 7, Week 48, n= 970.5 ± 3.28
Chloride, Year 8, Week 24, n= 600.5 ± 3.21
Chloride, Year 8, Week 48, n= 281.1 ± 2.49
Chloride, Year 9, Week 24, n= 21.5 ± 2.12
Chloride, Exit, n= 235-0.5 ± 2.96
Chloride, 8 Week, Follow-Up, n= 1070.1 ± 2.65
Magnesium, Year 1, Week 4, n= 2510.002 ± 0.0673
Magnesium, Year 1, Week 12, n= 248-0.005 ± 0.0625
Magnesium, Year 1, Week 24, n= 2460.004 ± 0.0599
Magnesium, Year 1, Week 36, n= 2380.001 ± 0.066
Magnesium, Year 1, Week 48, n= 2500.001 ± 0.0677
Magnesium, Year 2, Week 24, n= 2480.003 ± 0.0709
Magnesium, Year 2, Week 48, n= 2330.003 ± 0.0699
Magnesium, Year 3, Week 24, n= 2180.007 ± 0.0719
Magnesium, Year 3, Week 48, n= 2090.011 ± 0.0681
Magnesium, Year 4, Week 24, n= 2070.009 ± 0.0682
Magnesium, Year 4, Week 48, n= 1940.012 ± 0.0692
Magnesium, Year 5, Week 24, n= 1840.017 ± 0.062
Magnesium, Year 5, Week 48, n= 1780.014 ± 0.0622
Magnesium, Year 6, Week 24, n= 1750.017 ± 0.067
Magnesium, Year 6, Week 48, n= 1340.003 ± 0.0664
Magnesium, Year 7, Week 24, n= 1230.004 ± 0.0691
Magnesium, Year 7, Week 48, n= 970.001 ± 0.0681
Magnesium, Year 8, Week 24, n= 60-0.006 ± 0.0644
Magnesium, Year 8, Week 48, n= 280.016 ± 0.0599
Magnesium, Year 9, Week 24, n= 20.02 ± 0.0283
Magnesium, Exit, n= 2350.03 ± 0.0676
Magnesium, 8 Week, Follow-Up, n= 1070.028 ± 0.0728
Phosphate, Year 1, Week 4, n= 2510.0165 ± 0.1857
Phosphate, Year 1, Week 12, n= 248-0.0065 ± 0.1851
Phosphate, Year 1, Week 24, n= 2460.0106 ± 0.2027
Phosphate, Year 1, Week 36, n= 238-0.0039 ± 0.1825
Phosphate, Year 1, Week 48, n= 2500.0019 ± 0.1926
Phosphate, Year 2, Week 24, n= 248-0.0133 ± 0.2219
Phosphate, Year 2, Week 48, n= 2330.0099 ± 0.1968
Phosphate, Year 3, Week 24, n= 2180.0033 ± 0.2129
Phosphate, Year 3, Week 48, n= 2090.0017 ± 0.221
Phosphate, Year 4, Week 24, n= 207-0.0022 ± 0.2145
Phosphate, Year 4, Week 48, n= 194-0.0102 ± 0.1765
Phosphate, Year 5, Week 24, n= 184-0.015 ± 0.1899
Phosphate, Year 5, Week 48, n= 178-0.0035 ± 0.1892
Phosphate, Year 6, Week 24, n= 175-0.004 ± 0.2153
Phosphate, Year 6, Week 48, n= 134-0.0139 ± 0.2097
Phosphate, Year 7, Week 24, n= 1230.0296 ± 0.1962
Phosphate, Year 7, Week 48, n= 970.031 ± 0.1875
Phosphate, Year 8, Week 24, n= 60-0.0223 ± 0.2186
Phosphate, Year 8, Week 48, n= 28-0.0054 ± 0.2093
Phosphate, Year 9, Week 24, n= 20.1467 ± 0.1893
Phosphate, Exit, n= 2350.0161 ± 0.2151
Phosphate, 8 Week, Follow-Up, n= 1070.0438 ± 0.2131
Potassium, Year 1, Week 4, n= 2420.07 ± 0.407
Potassium, Year 1, Week 12, n= 2450.02 ± 0.412
Potassium, Year 1, Week 24, n= 2440.02 ± 0.409
Potassium, Year 1, Week 36, n= 2340.03 ± 0.427
Potassium, Year 1, Week 48, n= 250-0.04 ± 0.413
Potassium, Year 2, Week 24, n= 2460.01 ± 0.42
Potassium, Year 2, Week 48, n= 2310.02 ± 0.426
Potassium, Year 3, Week 24, n= 2150.01 ± 0.418
Potassium, Year 3, Week 48, n= 2050.01 ± 0.466
Potassium, Year 4, Week 24, n= 204-0.02 ± 0.409
Potassium, Year 4, Week 48, n= 1910.04 ± 0.417
Potassium, Year 5, Week 24, n= 1840 ± 0.406
Potassium, Year 5, Week 48, n= 1760.06 ± 0.427
Potassium, Year 6, Week 24, n= 172-0.03 ± 0.431
Potassium, Year 6, Week 48, n= 1340.06 ± 0.438
Potassium, Year 7, Week 24, n= 1210.04 ± 0.379
Potassium, Year 7, Week 48, n= 970.06 ± 0.387
Potassium, Year 8, Week 24, n= 600 ± 0.354
Potassium, Year 8, Week 48, n= 280.1 ± 0.401
Potassium, Year 9, Week 24, n= 20.05 ± 0.212
Potassium, Exit, n= 2350.11 ± 0.431
Potassium, 8 Week, Follow-Up, n= 1070.07 ± 0.493
Sodium, Year 1, Week 4, n= 2510.4 ± 2.67
Sodium, Year 1, Week 12, n= 2480 ± 2.67
Sodium, Year 1, Week 24, n= 2460.3 ± 2.02
Sodium, Year 1, Week 36, n= 2380.3 ± 2.46
Sodium, Year 1, Week 48, n= 250-0.1 ± 2.06
Sodium, Year 2, Week 24, n= 2480 ± 2.19
Sodium, Year 2, Week 48, n= 2330 ± 2.58
Sodium, Year 3, Week 24, n= 218-0.1 ± 2.18
Sodium, Year 3, Week 48, n= 2090.4 ± 2.44
Sodium, Year 4, Week 24, n= 2070.2 ± 2.54
Sodium, Year 4, Week 48, n= 1940.1 ± 2.36
Sodium, Year 5, Week 24, n= 1840.1 ± 2.19
Sodium, Year 5, Week 48, n= 1780 ± 2.37
Sodium, Year 6, Week 24, n= 1750.1 ± 2.33
Sodium, Year 6, Week 48, n= 1340.3 ± 2.72
Sodium, Year 7, Week 24, n= 1230.3 ± 2.97
Sodium, Year 7, Week 48, n= 970.3 ± 2.49
Sodium, Year 8, Week 24, n= 600.2 ± 2.32
Sodium, Year 8, Week 48, n= 280.4 ± 1.95
Sodium, Year 9, Week 24, n= 2-1 ± 1.41
Sodium, Exit, n= 2350.1 ± 2.32
Sodium, 8 Week, Follow-Up, n= 1070.8 ± 2.33
PrimaryChange From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points

Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in urate, creatinine and bilirubin is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

Time frame:
Up to Week 440
Reported as:
Mean · Micromoles per liter
Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points
Micromoles per literBelimumab 10 mg/kg IV
Creatinine, Year 1, Week 4, n= 250-0.2 ± 4.69
Creatinine, Year 1, Week 12, n= 248-0.5 ± 4.86
Creatinine, Year 1, Week 24, n= 246-0.6 ± 5.31
Creatinine, Year 1, Week 36, n= 237-0.4 ± 5.07
Creatinine, Year 1, Week 48, n= 250-0.2 ± 5.29
Creatinine, Year 2, Week 24, n= 248-0.2 ± 5.76
Creatinine, Year 2, Week 48, n= 2330.3 ± 4.78
Creatinine, Year 3, Week 24, n= 2180.8 ± 5.63
Creatinine, Year 3, Week 48, n= 2090.9 ± 5.61
Creatinine, Year 4, Week 24, n= 2071.2 ± 5.86
Creatinine, Year 4, Week 48, n= 1940.9 ± 6.05
Creatinine, Year 5, Week 24, n= 1841 ± 5.52
Creatinine, Year 5, Week 48, n= 1781.2 ± 6.49
Creatinine, Year 6, Week 24, n= 1751.2 ± 5.79
Creatinine, Year 6, Week 48, n= 1341 ± 6.38
Creatinine, Year 7, Week 24, n= 1231.1 ± 5.75
Creatinine, Year 7, Week 48, n= 970.7 ± 5.42
Creatinine, Year 8, Week 24, n= 600.8 ± 5.09
Creatinine, Year 8, Week 48, n= 280.4 ± 5.28
Creatinine, Year 9, Week 24, n= 2-0.5 ± 0.71
Creatinine, Exit, n= 2351.1 ± 5.57
Creatinine, 8 Week, Follow-Up, n= 1071.3 ± 5.99
Urate, Year 1, Week 4, n= 251-1.653 ± 46.0197
Urate, Year 1, Week 12, n= 248-5.5803 ± 52.2256
Urate, Year 1, Week 24, n= 246-11.6488 ± 55.2277
Urate, Year 1, Week 36, n= 238-9.984 ± 57.2999
Urate, Year 1, Week 48, n= 250-4.108 ± 58.0533
Urate, Year 2, Week 24, n= 248-6.4785 ± 57.0915
Urate, Year 2, Week 48, n= 233-4.6501 ± 60.3008
Urate, Year 3, Week 24, n= 2181.6919 ± 63.7367
Urate, Year 3, Week 48, n= 209-4.5543 ± 66.183
Urate, Year 4, Week 24, n= 207-4.8112 ± 60.2771
Urate, Year 4, Week 48, n= 194-2.0736 ± 60.7226
Urate, Year 5, Week 24, n= 184-5.296 ± 65.2308
Urate, Year 5, Week 48, n= 178-5.7908 ± 65.6118
Urate, Year 6, Week 24, n= 175-2.084 ± 73.3489
Urate, Year 6, Week 48, n= 134-8.7672 ± 74.9078
Urate, Year 7, Week 24, n= 123-2.0775 ± 72.282
Urate, Year 7, Week 48, n= 97-0.1021 ± 60.8139
Urate, Year 8, Week 24, n= 602.0387 ± 66.4246
Urate, Year 8, Week 48, n= 281.1266 ± 62.7192
Urate, Year 9, Week 24, n= 2-1.782 ± 16.402
Urate, Exit, n= 235-7.3728 ± 71.4811
Urate, 8 Week, Follow-Up, n= 107-6.6934 ± 84.8414
Bilirubin, Year 1, Week 4, n= 2510.008 ± 2.0889
Bilirubin, Year 1, Week 12, n= 2480.165 ± 2.4872
Bilirubin, Year 1, Week 24, n= 2460.075 ± 2.2546
Bilirubin, Year 1, Week 36, n= 2380.124 ± 2.4316
Bilirubin, Year 1, Week 48, n= 2500.231 ± 2.3675
Bilirubin, Year 2, Week 24, n= 2480.359 ± 2.7306
Bilirubin, Year 2, Week 48, n= 2330.307 ± 3.0385
Bilirubin, Year 3, Week 24, n= 2180.249 ± 2.8298
Bilirubin, Year 3, Week 48, n= 209-0.115 ± 2.548
Bilirubin, Year 4, Week 24, n= 207-0.276 ± 2.6718
Bilirubin, Year 4, Week 48, n= 194-0.156 ± 2.823
Bilirubin, Year 5, Week 24, n= 184-0.147 ± 2.8668
Bilirubin, Year 5, Week 48, n= 1780.13 ± 2.7449
Bilirubin, Year 6, Week 24, n= 175-0.067 ± 2.7954
Bilirubin, Year 6, Week 48, n= 1340.268 ± 2.6834
Bilirubin, Year 7, Week 24, n= 123-0.071 ± 2.7018
Bilirubin, Year 7, Week 48, n= 970.285 ± 2.85
Bilirubin, Year 8, Week 24, n= 600.529 ± 2.8249
Bilirubin, Year 8, Week 48, n= 280.175 ± 2.4435
Bilirubin, Year 9, Week 24, n= 2-0.45 ± 1.4142
Bilirubin, Exit, n= 2350.403 ± 2.8268
Bilirubin, 8 Week, Follow-Up, n= 107-0.191 ± 3.2759
PrimaryChange From Baseline in Creatinine Clearance at the Indicated Time Points

Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in creatinine clearance is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

Time frame:
Up to Week 440
Reported as:
Mean · Milliliters per second
Change From Baseline in Creatinine Clearance at the Indicated Time Points
Milliliters per secondBelimumab 10 mg/kg IV
Creatinine clearance, Year 1, Week 4, n= 251-0.022 ± 0.2312
Creatinine clearance, Year 1, Week 12, n= 2480.01 ± 0.2455
Creatinine clearance, Year 1, Week 24, n= 2460.028 ± 0.2831
Creatinine clearance, Year 1, Week 36, n= 2380.034 ± 0.3083
Creatinine clearance, Year 1, Week 48, n= 2500.017 ± 0.306
Creatinine clearance, Year 2, Week 24, n= 2480.047 ± 0.3145
Creatinine clearance, Year 2, Week 48, n= 2330.04 ± 0.3498
Creatinine clearance, Year 3, Week 24, n= 2180.093 ± 0.38
Creatinine clearance, Year 3, Week 48, n= 2090.093 ± 0.3784
Creatinine clearance, Year 4, Week 24, n= 2070.13 ± 0.3981
Creatinine clearance, Year 4, Week 48, n= 1940.084 ± 0.3628
Creatinine clearance, Year 5, Week 24, n= 1840.087 ± 0.3724
Creatinine clearance, Year 5, Week 48, n= 1780.04 ± 0.3652
Creatinine clearance, Year 6, Week 24, n= 1750.035 ± 0.3971
Creatinine clearance, Year 6, Week 48, n= 1340.039 ± 0.3985
Creatinine clearance, Year 7, Week 24, n= 123-0.007 ± 0.4482
Creatinine clearance, Year 7, Week 48, n= 970.005 ± 0.4424
Creatinine clearance, Year 8, Week 24, n= 60-0.018 ± 0.4682
Creatinine clearance, Year 8, Week 48, n= 28-0.042 ± 0.2808
Creatinine clearance, Year 9, Week 24, n= 2-0.083 ± 0.165
Creatinine clearance, Exit, n= 2350.011 ± 0.3986
Creatinine clearance, 8 Week, Follow-Up, n= 1060.036 ± 0.3467
PrimaryChange From Baseline in BUN/Creatinine at the Indicated Time Points

Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in BUN/creatinine is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

Time frame:
Up to Week 440
Reported as:
Mean · Ratio
Change From Baseline in BUN/Creatinine at the Indicated Time Points
RatioBelimumab 10 mg/kg IV
BUN/creatinine, Year 1, Week 4, n= 251-0.2 ± 4.69
BUN/creatinine, Year 1, Week 12, n= 248-0.5 ± 4.86
BUN/creatinine, Year 1, Week 24, n= 246-0.6 ± 5.31
BUN/creatinine, Year 1, Week 36, n= 238-0.4 ± 5.07
BUN/creatinine, Year 1, Week 48, n= 250-0.2 ± 5.29
BUN/creatinine, Year 2, Week 24, n= 248-0.2 ± 5.76
BUN/creatinine, Year 2, Week 48, n= 2330.3 ± 4.78
BUN/creatinine, Year 3, Week 24, n= 2180.8 ± 5.63
BUN/creatinine, Year 3, Week 48, n= 2090.9 ± 5.61
BUN/creatinine, Year 4, Week 24, n= 2071.2 ± 5.86
BUN/creatinine, Year 4, Week 48, n= 1940.9 ± 6.05
BUN/creatinine, Year 5, Week 24, n= 1841 ± 5.52
BUN/creatinine, Year 5, Week 48, n= 1781.2 ± 6.49
BUN/creatinine, Year 6, Week 24, n= 1751.2 ± 5.79
BUN/creatinine, Year 6, Week 48, n= 1341 ± 6.38
BUN/creatinine, Year 7, Week 24, n= 1231.1 ± 5.75
BUN/creatinine, Year 7, Week 48, n= 970.7 ± 5.42
BUN/creatinine, Year 8, Week 24, n= 600.8 ± 5.09
BUN/creatinine, Year 8, Week 48, n= 280.4 ± 5.28
BUN/creatinine, Year 9, Week 24, n= 2-0.5 ± 0.71
BUN/creatinine, Exit, n= 2351.1 ± 5.57
BUN/creatinine, 8 Week, Follow-Up, n= 1071.3 ± 5.99
PrimaryChange From Baseline in Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase and Lactate Dehydrogenase at the Indicated Time Points

Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit. Change from Baseline in alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, gamma glutamyl transferase and lactate dehydrogenase is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

Time frame:
Up to Week 432
Reported as:
Mean · Units per liter
Change From Baseline in Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase and Lactate Dehydrogenase at the Indicated Time Points
Units per literBelimumab 10 mg/kg IV
Alanine aminotransferase, Year 1, Week 4, n= 2510.5 ± 14.89
Alanine aminotransferase, Year 1, Week 12, n= 248-0.5 ± 11.01
Alanine aminotransferase, Year 1, Week 24, n= 246-0.1 ± 12.27
Alanine aminotransferase, Year 1, Week 36, n= 2380.3 ± 14.12
Alanine aminotransferase, Year 1, Week 48, n= 2500.4 ± 14.64
Alanine aminotransferase, Year 2, Week 24, n= 2480.8 ± 12.33
Alanine aminotransferase, Year 2, Week 48, n= 2331.7 ± 16.67
Alanine aminotransferase, Year 3, Week 24, n= 2180.9 ± 12.32
Alanine aminotransferase, Year 3, Week 48, n= 2090.4 ± 14.93
Alanine aminotransferase, Year 4, Week 24, n= 2071.7 ± 17.02
Alanine aminotransferase, Year 4, Week 48, n= 1942.4 ± 24.4
Alanine aminotransferase, Year 5, Week 24, n= 1841.8 ± 15.79
Alanine aminotransferase, Year 5, Week 48, n= 1780.3 ± 17.15
Alanine aminotransferase, Year 6, Week 24, n= 1751 ± 20.87
Alanine aminotransferase, Year 6, Week 48, n= 134-0.1 ± 13.25
Alanine aminotransferase, Year 7, Week 24, n= 123-2.8 ± 13.96
Alanine aminotransferase, Year 7, Week 48, n= 97-2.8 ± 15.06
Alanine aminotransferase, Year 8, Week 24, n= 60-5.1 ± 12.06
Alanine aminotransferase, Year 8, Week 48, n= 28-0.6 ± 11.39
Alanine aminotransferase, Year 9, Week 24, n= 25 ± 4.24
Alanine aminotransferase, Exit, n= 235-1.2 ± 13.77
Alanine aminotransferase, 8 Week, Follow-Up, n= 100.1 ± 14.46
Alkaline phosphatase, Year 1, Week 4, n= 251-0.8 ± 13.82
Alkaline phosphatase, Year 1, Week 12, n= 2480.4 ± 17.41
Alkaline phosphatase, Year 1, Week 24, n= 2460.3 ± 16.72
Alkaline phosphatase, Year 1, Week 36, n= 2381.2 ± 16.2
Alkaline phosphatase, Year 1, Week 48, n= 2503.3 ± 19.97
Alkaline phosphatase, Year 2, Week 24, n= 2484.9 ± 21.17
Alkaline phosphatase, Year 2, Week 48, n= 2335.8 ± 21.25
Alkaline phosphatase, Year 3, Week 24, n= 2185.4 ± 20.61
Alkaline phosphatase, Year 3, Week 48, n= 2093.1 ± 21.89
Alkaline phosphatase, Year 4, Week 24, n= 2076.5 ± 29.67
Alkaline phosphatase, Year 4, Week 48, n= 1946.2 ± 33.31
Alkaline phosphatase, Year 5, Week 24, n= 1847.8 ± 24.75
Alkaline phosphatase, Year 5, Week 48, n= 1786.7 ± 26.55
Alkaline phosphatase, Year 6, Week 24, n= 1757.5 ± 33.87
Alkaline phosphatase, Year 6, Week 48, n= 1346.6 ± 26.36
Alkaline phosphatase, Year 7, Week 24, n= 1235.5 ± 25
Alkaline phosphatase, Year 7, Week 48, n= 975.2 ± 24.83
Alkaline phosphatase, Year 8, Week 24, n= 602.3 ± 29.63
Alkaline phosphatase, Year 8, Week 48, n= 280.3 ± 38.97
Alkaline phosphatase, Year 9, Week 24, n= 219.5 ± 24.75
Alkaline phosphatase, Exit, n= 2354.6 ± 23.59
Alkaline phosphatase, 8 Week, Follow-Up, n= 1072.8 ± 26.98
Aspartate aminotransferase ,Year 1, Week 4, n= 2420.3 ± 11.18
Aspartate aminotransferase ,Year 1,Week 12, n= 245-0.6 ± 9.37
Aspartate aminotransferase ,Year 1,Week 24, n= 244-0.8 ± 8.14
Aspartate aminotransferase,Year 1,Week 36,n=234-0.3 ± 11.29
Aspartate aminotransferase ,Year 1,Week 48, n= 250-0.2 ± 10.67
Aspartate aminotransferase , Year 2, Week 24,n=2460.4 ± 10.97
Aspartate aminotransferase , Year 2, Week 48,n=2311 ± 12.24
Aspartate aminotransferase , Year 3,Week 24,n=2150.2 ± 9.49
Aspartate aminotransferase ,Year 3,Week 48, n= 2050.1 ± 14.63
Aspartate aminotransferase , Year 4,Week 24, n=2041.3 ± 14.74
Aspartate aminotransferase , Year 4, Week 48,n=1913.7 ± 32.99
Aspartate aminotransferase , Year 5,Week 24, n=1841.7 ± 16.27
Aspartate aminotransferase , Year 5,Week 48, n=1760.6 ± 15.15
Aspartate aminotransferase , Year 6,Week 24,n= 1722.4 ± 22.03
Aspartate aminotransferase , Year 6,Week 48, n=1341 ± 13.55
Aspartate aminotransferase , Year 7,Week 24,n=121-0.6 ± 13.14
Aspartate aminotransferase , Year 7, Week 48, n=97-1.1 ± 14.1
Aspartate aminotransferase , Year 8, Week 24,n=60-2.7 ± 9.66
Aspartate aminotransferase , Year 8, Week 48, n=280.1 ± 8.02
Aspartate aminotransferase , Year 9, Week 24, n= 25 ± 4.24
Aspartate aminotransferase , Exit, n= 235-0.4 ± 15.07
Aspartate aminotransferase,8 Week,Follow-Up, n=107-0.7 ± 12.45
Gamma glutamyl transferase, Year 1, Week 4, n= 2510.5 ± 22.54
Gamma glutamyl transferase, Year 1,Week 12, n= 2480.5 ± 21.44
Gamma glutamyl transferase, Year 1,Week 24, n= 246-1.3 ± 20.21
Gamma glutamyl transferase, Year 1, Week 36, n=238-0.1 ± 18.64
Gamma glutamyl transferase, Year 1, Week 48, n=2502.2 ± 39.98
Gamma glutamyl transferase, Year 2,Week 24, n= 2481.2 ± 27.97
Gamma glutamyl transferase, Year 2, Week 48,n= 2331.9 ± 28.88
Gamma glutamyl transferase, Year 3, Week 24, n=2181.8 ± 20.1
Gamma glutamyl transferase, Year 3, Week 48, n=209-2.4 ± 31.27
Gamma glutamyl transferase, Year 4, Week 24, n=2072.5 ± 45.58
Gamma glutamyl transferase, Year 4, Week 48, n=1941.5 ± 47.03
Gamma glutamyl transferase, Year 5,Week 24, n= 184-0.4 ± 32.51
Gamma glutamyl transferase, Year 5, Week 48, n=1780.6 ± 40.11
Gamma glutamyl transferase, Year 6, Week 24, n=175-3.3 ± 40.3
Gamma glutamyl transferase, Year 6, Week 48, n=134-4.4 ± 37.08
Gamma glutamyl transferase, Year 7, Week 24, n=123-7.2 ± 38.88
Gamma glutamyl transferase, Year 7, Week 48, n= 97-8.8 ± 36.19
Gamma glutamyl transferase, Year 8, Week 24, n= 60-12.9 ± 35.44
Gamma glutamyl transferase, Year 8, Week 48, n= 28-6.9 ± 31.02
Gamma glutamyl transferase, Year 9, Week 24, n= 22.5 ± 3.54
Gamma glutamyl transferase, Exit, n= 235-2.2 ± 35.29
Gamma glutamyl transferase, 8 Week,Follow-Up,n=1072.1 ± 35.9
Lactate dehydrogenase , Year 1, Week 4, n= 2420.2 ± 26.46
Lactate dehydrogenase , Year 1, Week 12, n= 245-2.4 ± 29.56
Lactate dehydrogenase , Year 1, Week 24, n= 244-2.2 ± 37.57
Lactate dehydrogenase , Year 1, Week 36, n= 234-2.8 ± 34.88
Lactate dehydrogenase , Year 1, Week 48, n= 250-4.3 ± 35.5
Lactate dehydrogenase , Year 2, Week 24, n= 246-4.8 ± 36.29
Lactate dehydrogenase , Year 2, Week 48, n= 231-5.4 ± 40.42
Lactate dehydrogenase , Year 3, Week 24, n= 215-8.1 ± 40.13
Lactate dehydrogenase , Year 3, Week 48, n= 205-9.2 ± 47.95
Lactate dehydrogenase , Year 4, Week 24, n= 204-7.7 ± 45.12
Lactate dehydrogenase , Year 4, Week 48, n= 191-4.7 ± 53.17
Lactate dehydrogenase , Year 5, Week 24, n= 184-5.5 ± 48.34
Lactate dehydrogenase , Year 5, Week 48, n= 176-10.3 ± 49.81
Lactate dehydrogenase , Year 6, Week 24, n= 172-2.7 ± 72.28
Lactate dehydrogenase , Year 6, Week 48, n= 134-5.3 ± 55.64
Lactate dehydrogenase , Year 7, Week 24, n= 121-7.9 ± 53.17
Lactate dehydrogenase , Year 7, Week 48, n= 97-9.5 ± 57.15
Lactate dehydrogenase , Year 8, Week 24, n= 60-11.2 ± 58.81
Lactate dehydrogenase , Year 8, Week 48, n= 28-5.5 ± 81.78
Lactate dehydrogenase , Year 9, Week 24, n= 2-9.5 ± 0.71
Lactate dehydrogenase , Exit, n= 235-6.5 ± 56.73
Lactate dehydrogenase , 8 Week, Follow-Up, n= 107-3.4 ± 52.66
PrimaryNumber of Participants With the Indicated Immunogenic Response

Immunogenic response was assessed by binding confirmatory assay at Baseline (BL) (Day 0), at Week 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Number of participants with the indicated immunogenic response are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Results of binding confirmatory assay were categorized as negative, persistent positive (defined as a positive immunogenic response that occurs at least 2 consecutive assessments or a single result at the final assessment) or transient positive (defined as a single positive immunogenic response that does not occur at the final assessment). Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

Time frame:
Up to Week 440
Reported as:
Number · Participants
Number of Participants With the Indicated Immunogenic Response
ParticipantsBelimumab 10 mg/kg IV
Negative, Year 0-1, n=267262
Negative, Year 1-2, n=255251
Negative, Year 2-3, n=240239
Negative, Year 3-4, n=214213
Negative, Year 4-5, n=195195
Negative, Year 5-6, n=185185
Negative, Year 6-7, n=125125
Negative, Year 7 plus, n=6363
Transient positive, Year 0-1, n=2675
Transient positive, Year 1-2, n=2554
Transient positive, Year 2-3, n=2400
Transient positive, Year 3-4, n=2141
Transient positive, Year 4-5, n=1950
Transient positive, Year 5-6, n=1850
Transient positive, Year 6-7, n=1250
Transient positive, Year 7 plus, n=630
Persistent positive, Year 0-1, n=2670
Persistent positive, Year 1-2, n=2550
Persistent positive, Year 2-3, n=2400
Persistent positive, Year 3-4, n=2140
Persistent positive, Year 4-5, n=1950
Persistent positive, Year 5-6, n=1850
Persistent positive, Year 6-7, n=1250
Persistent positive, Year 7 plus, n=630
Unknown, Year 0-1, n=2670
Unknown, Year 1-2, n=2550
Unknown, Year 2-3, n=2401
Unknown, Year 3-4, n=2140
Unknown, Year 4-5, n=1950
Unknown, Year 5-6, n=1850
Unknown, Year 6-7, n=1250
Unknown, Year 7 plus, n=630
PrimarySystolic Blood Pressure and Diastolic Blood Pressure at Indicated Time Points.

Systolic blood pressure (SBP) and diastolic blood pressure (DBP) was measured at Baseline (BL) (Day 0), at Week 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

Time frame:
Up to Week 432
Reported as:
Mean · Millimeters of mercury
Systolic Blood Pressure and Diastolic Blood Pressure at Indicated Time Points.
Millimeters of mercuryBelimumab 10 mg/kg IV
DBP, Baseline, n= 26874.3 ± 9.92
DBP, Year 1 , Week 24, n= 25574.5 ± 9.96
DBP, Year 1 , Week 48, n= 25573.5 ± 9.92
DBP, Year 2 , Week 24, n= 25174.5 ± 11.01
DBP, Year 2 , Week 48, n= 23673.5 ± 10.17
DBP, Year 3 , Week 24, n= 22373.6 ± 10.32
DBP, Year 3 , Week 48, n= 21473.4 ± 10.12
DBP, Year 4 , Week 24, n= 21474.4 ± 9.56
DBP, Year 4 , Week 48, n= 19975.2 ± 10.52
DBP, Year 5 , Week 24, n= 18774.3 ± 9.89
DBP, Year 5 , Week 48, n= 18573.4 ± 10.15
DBP, Year 6 , Week 24, n= 17874.1 ± 10.25
DBP, Year 6 , Week 48, n= 13873.9 ± 10.78
DBP, Year 7 , Week 24, n= 12475.2 ± 9.5
DBP, Year 7 , Week 48, n= 9873.1 ± 9.94
DBP, Year 8 , Week 24, n= 6073.4 ± 9.79
DBP, Year 8 , Week 48, n= 2973.6 ± 8.27
DBP, Year 9 , Week 24, n= 290 ± 12.73
DBP, Exit, n= 23375.2 ± 9.77
SBP, Baseline, n= 268119.7 ± 15.75
SBP, Year 1 , Week 24, n= 255120 ± 16.14
SBP, Year 1 , Week 48, n= 255120.2 ± 14.66
SBP, Year 2 , Week 24, n= 251120.1 ± 16.49
SBP, Year 2 , Week 48, n= 236119.1 ± 15.22
SBP, Year 3 , Week 24, n= 223120.7 ± 16.23
SBP, Year 3 , Week 48, n= 214120.2 ± 14.44
SBP, Year 4 , Week 24, n= 214121.4 ± 14.61
SBP, Year 4 , Week 48, n= 199121.4 ± 15.03
SBP, Year 5 , Week 24, n= 187120.7 ± 14.92
SBP, Year 5 , Week 48, n= 185119.9 ± 15.29
SBP, Year 6 , Week 24, n= 178121.5 ± 15.29
SBP, Year 6 , Week 48, n= 138121.7 ± 15.86
SBP, Year 7 , Week 24, n= 124121.6 ± 14.73
SBP, Year 7 , Week 48, n= 98120.6 ± 14.19
SBP, Year 8 , Week 24, n= 60120.5 ± 14.65
SBP, Year 8 , Week 48, n= 29118.2 ± 11.73
SBP, Year 9 , Week 24, n= 2115.5 ± 6.36
SBP, Exit, n= 233123.3 ± 15.53
PrimaryPercentage of Participants With at Least 25% Increase From Baseline in Creatinine at Indicated Time Points.

Serum creatinine was assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Percentage of participants with at least 25% increase from baseline in creatinine are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

Time frame:
Up to Week 440
Reported as:
Number · Percentage of Participants
Percentage of Participants With at Least 25% Increase From Baseline in Creatinine at Indicated Time Points.
Percentage of ParticipantsBelimumab 10 mg/kg IV (Placebo)Belimumab 10 mg/kg IV (Belimumab)
Year 0-1, n= 91, 1777.723.2
Year 1-2, n= 79, 1773.820.3
Year 2-3, n= 75, 1682.78.3
Year 3-4, n= 68, 1504.46
Year 4-5, n= 61, 1394.99.4
Year 5-6, n= 59, 1325.19.1
Year 6-7, n= 12, 1188.311.9
Year 7+, n= 0, 65010.8
PrimaryPercentage of Participants With at Least 25% Reduction From Baseline in Creatinine at Indicated Time Points. Amongst Subjects With Abnormal (>124 Umol/L) Creatinine at Baseline by Year Interval.

Serum creatinine was assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Percentage of participants with at least 25% reduction from baseline in creatinine are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

Time frame:
Up to Week 440
Reported as:
Number · Percentage of Participants
Percentage of Participants With at Least 25% Reduction From Baseline in Creatinine at Indicated Time Points. Amongst Subjects With Abnormal (>124 Umol/L) Creatinine at Baseline by Year Interval.
Percentage of ParticipantsBelimumab 10 mg/kg IV (Placebo)Belimumab 10 mg/kg IV (Belimumab)
Year 0-1, n= 6, 316.733.3
Year 1-2, n= 5, 3200
Year 2-3, n= 3, 333.30
Year 3-4, n= 2, 2050
Year 4-5, n= 2, 2050
Year 5-6, n= 2, 2500
Year 6-7, n= 1, 10100
Year 7+, n= 0, 000
SecondaryNumber of Participants With Serum Immunoglobulins Below the Lower Limit of Normal at Indicated Time Points.

Serum immunoglobulin G (IgG) was collected at Baseline (BL) (Day 0), at Week 24 and Week 48 in first year, at Week 48 in subsequent years up to 8 years and at follow-up (up to 8 weeks post last infusion). Number of participants with serum immunoglobulins below the lower limit of normal (LLN) (\<0.5 nanograms per milliliter \[ng/mL\]) are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

Time frame:
Up to Week 392
Reported as:
Number · Participants
Number of Participants With Serum Immunoglobulins Below the Lower Limit of Normal at Indicated Time Points.
ParticipantsBelimumab 10 mg/kg IV
Baseline, n=2688
Year 1, Week 24, n= 25214
Year 1, Week 48, n= 25516
Year 2, Week 48, n= 23719
Year 3, Week 48, n= 22417
Year 4, Week 48, n= 20826
Year 5, Week 48, n= 19019
Year 6, Week 48, n= 15021
Year 7, Week 48, n= 11221
Year 8, Week 48, n= 595
Exit, n= 23529
8 Week Follow-Up, n= 10610
SecondaryPercentage of Participants Achieving SRI Response at Indicated Time Points

The percentage of participants achieving a SLE Responder Index (SRI) response at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion) are summarized. The BL is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Response is defined as:\>=4 point reduction from the BL in the safety of estrogen in lupus national assessment (SELENA) SLE disease activity index (SLEDAI) score and no worsening (increase of \<0.30 points from the BL) in Physicians Global Assessment (PGA), and no new British Isles Lupus Assessment Group (BILAG) A organ domain score or 2 new BILAG B organ domain scores compared with the BL. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

Time frame:
Up to Week 440
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving SRI Response at Indicated Time Points
Percentage of ParticipantsBelimumab 10 mg/kg IV
Year 1 , Week 24, n= 22941.9
Year 1 , Week 48, n= 22545.3
Year 2 , Week 24, n= 22749.3
Year 2 , Week 48, n= 20449
Year 3 , Week 24, n= 21151.2
Year 3 , Week 48, n= 18558.4
Year 4 , Week 24, n= 18856.9
Year 4 , Week 48, n= 17464.9
Year 5 , Week 24, n= 16866.7
Year 5 , Week 48, n= 15762.4
Year 6 , Week 24, n= 16469.5
Year 6 , Week 48, n= 12374
Year 7 , Week 24, n= 11975.6
Year 7 , Week 48, n= 9378.5
Year 8 , Week 24, n= 6366.7
Year 8 , Week 48, n= 2965.5
Year 9 , Week 24, n= 20
SecondaryObserved Anti-double Stranded DNA Levels at Indicated Time Points.

Anti-double stranded deoxyribonucleic acid (anti-dsDNA) levels were assessed at Baseline (BL) (Day 0), at Week 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks in participants who were positive at baseline (anti-dsDNA \>=30 International Units/milliliter \[IU/mL\]). Observed anti-dsDNA levels are summarized. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

Time frame:
Up to Week 432
Reported as:
Median · International units per milliliter
Observed Anti-double Stranded DNA Levels at Indicated Time Points.
International units per milliliterBelimumab 10 mg/kg IV
Baseline, n= 135193 (34 to 201)
Year 1, Week 24, n= 128127.5 (29 to 201)
Year 1, Week 48, n= 130123 (29 to 201)
Year 2, Week 24, n= 12693.5 (29 to 349)
Year 2, Week 48, n= 12895 (5 to 2505)
Year 3, Week 24, n= 12082.5 (5 to 1545)
Year 3, Week 48, n= 11686.5 (5 to 556)
Year 4, Week 24, n= 11287.5 (5 to 2305)
Year 4, Week 48, n= 10076.5 (5 to 1873)
Year 5, Week 24, n= 9860 (5 to 1188)
Year 5, Week 48, n= 9647.5 (5 to 1765)
Year 6, Week 24, n= 8747 (5 to 1863)
Year 6, Week 48, n= 6650 (5 to 1018)
Year 7, Week 24, n= 6335 (5 to 2648)
Year 7, Week 48, n= 4832 (5 to 736)
Year 8, Week 24, n= 3529 (5 to 521)
Year 8, Week 48, n= 1650.5 (5 to 439)
Year 9, Week 24, n= 145 (45 to 45)
Exit, n= 12037 (5 to 1608)
SecondaryMedian Percent Change From Baseline in Anti-double Stranded DNA at Indicated Time Points.

Anti-dsDNA levels were assessed at Baseline (BL) (Day 0), 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit in participants who were positive at baseline (anti-dsDNA ≥30 IU/mL). Median percent change from Baseline in anti-dsDNA levels are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Percent change from Baseline is calculated as: 100 x (\[Post-Dose Visit Value - Baseline\] / Baseline). Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

Time frame:
Up to Week 432
Reported as:
Median · Percentage change
Median Percent Change From Baseline in Anti-double Stranded DNA at Indicated Time Points.
Percentage changeBelimumab 10 mg/kg IV
Year 1, Week 24, n= 128-9.77 (-75.6 to 54.6)
Year 1, Week 48, n= 130-15.58 (-84.2 to 183.1)
Year 2, Week 24, n= 126-27.5 (-84.7 to 181.7)
Year 2, Week 48, n= 128-30.12 (-90.6 to 1253.6)
Year 3, Week 24, n= 120-34.22 (-90.6 to 668.7)
Year 3, Week 48, n= 116-34.92 (-90.6 to 176.6)
Year 4, Week 24, n= 112-38.58 (-90.6 to 1046.8)
Year 4, Week 48, n= 100-54.46 (-96 to 831.8)
Year 5, Week 24, n= 98-54.39 (-96.5 to 491)
Year 5, Week 48, n= 96-64.43 (-97.5 to 778.1)
Year 6, Week 24, n= 87-64.04 (-97.5 to 826.9)
Year 6, Week 48, n= 66-64.91 (-97.5 to 406.5)
Year 7, Week 24, n= 63-74.74 (-97.5 to 1217.4)
Year 7, Week 48, n= 48-78.15 (-97.5 to 557.1)
Year 8, Week 24, n= 35-79.1 (-97.5 to 365.2)
Year 8, Week 48, n= 16-72.38 (-97.5 to 292)
Year 9, Week 24, n= 1-77.6 (-77.6 to -77.6)
Exit, n= 120-66.67 (-97.5 to 700)
SecondaryObserved Complement C3 and C4 Levels at Indicated Time Points

Complement C3 and C4 levels were assessed at Baseline (BL) (Day 0), at Week 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at exit visit in participants with low complements at Baseline (C3 \<90 milligram per deciliter (mg/dL) and C4 \<16 mg/dL). Observed complement C3 and C4 levels are summarized. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

Time frame:
Up to Week 440
Reported as:
Median · Milligrams per deciliter
Observed Complement C3 and C4 Levels at Indicated Time Points
Milligrams per deciliterBelimumab 10 mg/kg IV
C3, Baseline, n= 8676 (40 to 89)
C3, Year 1, Week 24, n= 8380 (43 to 160)
C3, Year 1, Week 48, n= 8386 (38 to 144)
C3, Year 2, Week 24, n= 8185 (46 to 157)
C3, Year 2, Week 48, n= 8088.5 (36 to 137)
C3, Year 3, Week 24, n= 7490.5 (55 to 133)
C3, Year 3, Week 48, n= 7393 (51 to 139)
C3, Year 4, Week 24, n= 7294 (47 to 150)
C3, Year 4, Week 48, n= 6695 (58 to 137)
C3, Year 5, Week 24, n= 6399 (64 to 193)
C3, Year 5, Week 48, n= 6197 (56 to 172)
C3, Year 6, Week 24, n= 5599 (54 to 161)
C3, Year 6, Week 48, n= 37103 (47 to 158)
C3, Year 7, Week 24, n= 41103 (50 to 147)
C3, Year 7, Week 48, n= 32110 (51 to 173)
C3, Year 8, Week 24, n= 20110.5 (76 to 177)
C3, Year 8, Week 48, n= 9104 (79 to 158)
C3, Exit, n= 74103 (56 to 173)
C4, Baseline, n=9810 (3 to 15)
C4, Year 1, Week 24, n=9513 (3 to 25)
C4, Year 1, Week 48, n=9315 (4 to 28)
C4, Year 2, Week 24, n=9315 (3 to 29)
C4, Year 2, Week 48, n=9416 (4 to 37)
C4, Year 3, Week 24, n=8415.5 (4 to 31)
C4, Year 3, Week 48, n=8316 (3 to 35)
C4, Year 4, Week 24, n=8116 (3 to 38)
C4, Year 4, Week 48, n=7117 (4 to 26)
C4, Year 5, Week 24, n=7018 (4 to 40)
C4, Year 5, Week 48, n=7018 (3 to 39)
C4, Year 6, Week 24, n=6218 (5 to 36)
C4, Year 6, Week 48, n=4518 (5 to 29)
C4, Year 7, Week 24, n=4919 (6 to 34)
C4, Year 7, Week 48, n=3519 (6 to 34)
C4, Year 8, Week 24, n=2420.5 (10 to 35)
C4, Year 8, Week 48, n=1218 (7 to 36)
C4, Year 9, Week 24, n=122 (22 to 22)
C4, Exit, n=8518 (4 to 41)
SecondaryMedian Percent Change From Baseline in Complement C3 and C4 Levels at Indicated Time Points

Complement C3 and C4 levels were assessed at Baseline (BL) (Day 0), 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit in participants with low complements at Baseline (C3 \<90 milligrams per decilitre (mg/dL) and C4 \<16 mg/dL). Median percent change from Baseline in complement C3 and C4 levels are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Percent change from Baseline is calculated as: 100 x (\[Post-Dose Visit Value - Baseline\] / Baseline). Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

Time frame:
Up to Week 432
Reported as:
Median · Percent Change
Median Percent Change From Baseline in Complement C3 and C4 Levels at Indicated Time Points
Percent ChangeBelimumab 10 mg/kg IV
C3, Year 1, Week 24, n= 8310.91 (-33 to 281)
C3, Year 1, Week 48, n= 8317.86 (-45.3 to 104.8)
C3, Year 2, Week 24, n= 8118.64 (-23.3 to 192.9)
C3, Year 2, Week 48, n= 8016.71 (-37.9 to 163.3)
C3, Year 3, Week 24, n= 7424.26 (-17.3 to 161.2)
C3, Year 3, Week 48, n= 7322.73 (-34.6 to 163.3)
C3, Year 4, Week 24, n= 7232.43 (-32.9 to 206.1)
C3, Year 4, Week 48, n= 6630.63 (-27.5 to 177.6)
C3, Year 5, Week 24, n= 6333.93 (-24.7 to 175.7)
C3, Year 5, Week 48, n= 6134.29 (-17.9 to 173.5)
C3, Year 6, Week 24, n= 5535.71 (-18 to 159.7)
C3, Year 6, Week 48, n= 3734.57 (-32.9 to 166.7)
C3, Year 7, Week 24, n= 4136.11 (-34.2 to 137.1)
C3, Year 7, Week 48, n= 3242.04 (-36.3 to 179)
C3, Year 8, Week 24, n= 2036.97 (7.7 to 185.5)
C3, Year 8, Week 48, n= 930.16 (5 to 163.3)
C3, Exit, n= 7439.05 (-25.6 to 195.2)
C4, Year 1, Week 24, n=9530.77 (-53.3 to 275)
C4, Year 1, Week 48, n=9340 (-40 to 200)
C4, Year 2, Week 24, n=9342.86 (-57.1 to 350)
C4, Year 2, Week 48, n=9447.73 (-33.3 to 270)
C4, Year 3, Week 24, n=8450 (-20 to 266.7)
C4, Year 3, Week 48, n=8346.15 (-40 to 250)
C4, Year 4, Week 24, n=8157.14 (-70 to 450)
C4, Year 4, Week 48, n=7158.33 (-42.9 to 433.3)
C4, Year 5, Week 24, n=7070.33 (-30 to 500)
C4, Year 5, Week 48, n=7065.15 (-40 to 566.7)
C4, Year 6, Week 24, n=6271.36 (-10 to 800)
C4, Year 6, Week 48, n=4557.14 (-40 to 600)
C4, Year 7, Week 24, n=4963.64 (-40 to 700)
C4, Year 7, Week 48, n=3562.5 (-14.3 to 900)
C4, Year 8, Week 24, n=2478.97 (0 to 900)
C4, Year 8, Week 48, n=1269.74 (-30 to 1100)
C4, Year 9, Week 24, n=1100 (100 to 100)
C4, Exit, n=8575 (-53.8 to 1066.7)
SecondaryPercent of Participants With Daily Prednisone Dose Reduction at Indicated Time Points.

Trends for reduction in prednisone use in participants receiving belimumab were observed up to 432 weeks. Percentage of participants with daily prednisone dose reduced to \<=7.5 mg/day from \>7.5 mg/kg at the Baseline are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

Time frame:
Up to Week 432
Reported as:
Number · Percentage of Participants
Percent of Participants With Daily Prednisone Dose Reduction at Indicated Time Points.
Percentage of ParticipantsBelimumab 10 mg/kg IV
Year 1, Week 24, n= 802.5
Year 1, Week 48, n= 8121
Year 2, Week 24, n= 7838.5
Year 2, Week 48, n= 7640.8
Year 3, Week 24, n= 6450
Year 3, Week 48, n= 6341.3
Year 4, Week 24, n= 6543.1
Year 4, Week 48, n= 6237.1
Year 5, Week 24, n= 5733.3
Year 5, Week 48, n= 5738.6
Year 6, Week 24, n= 5534.5
Year 6, Week 48, n= 4742.6
Year 7, Week 24, n= 4238.1
Year 7, Week 48, n= 3839.5
Year 8, Week 24, n= 2450
Year 8, Week 48, n= 1258.3
Year 9, Week 24, n= 2100
SecondaryPercent of Participants With >= 50% Reduction in Proteinuria at Indicated Time Points.

Proteinuria is defined as the presence of an excess of serum proteins in the urine. Trends for reduction in proteinuria in participants receiving belimumab were assessed up to 432 weeks and at Exit visit. Percentage of participants with \>= 50% reduction in proteinuria among participants with Baseline proteinuria \>0.5 g/24 hour (hr) are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

Time frame:
Up to Week 432
Reported as:
Number · Percentage of Participants
Percent of Participants With >= 50% Reduction in Proteinuria at Indicated Time Points.
Percentage of ParticipantsBelimumab 10 mg/kg IV
Year 1, Week 24, n=3441.2
Year 1, Week 48, n=3363.6
Year 2, Week 24, n=3360.6
Year 2, Week 48, n=3053.3
Year 3, Week 24, n=3174.2
Year 3, Week 48, n=2867.9
Year 4, Week 24, n=2588
Year 4, Week 48, n=2373.9
Year 5, Week 24, n=2373.9
Year 5, Week 48, n=2286.4
Year 6, Week 24, n=2277.3
Year 6, Week 48, n=1776.5
Year 7, Week 24, n=1478.6
Year 7, Week 48, n=771.4
Year 8, Week 24, n=475
Year 8, Week 48, n=1100
Year 9, Week 24, n=2864.3
SecondaryObserved B-cell Levels at Indicated Time Points.

B-cell levels were assessed at Baseline (BL) (Day 0), Week (Wk) 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit. Observed absolute B cell subsets (CD20+), CD19+/27BRIGHT/38BRIGHT SLE subset, CD19+20-27hi+ short-lived plasma cells (SLPC), CD20+/138+ plasmacytoid, CD20+/27+ memory, CD20+/27- naïve, CD20+/69+activated, CD20-/138+ plasma cells, Total CD19+ B-cells (CD19+) levels are summarized. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

Time frame:
Up to Week 432
Reported as:
Median · Cell count
Observed B-cell Levels at Indicated Time Points.
Cell countBelimumab 10 mg/kg IV
CD20+, Baseline, n= 262112.5 (2 to 807)
CD20+, Yr 1, Wk 24, n= 25168 (2 to 433)
CD20+, Yr 1, Wk 48, n= 24250 (2 to 407)
CD20+, Yr 2, Wk 24, n= 23837.5 (5 to 278)
CD20+, Yr 2, Wk 48, n= 22434 (5 to 1528)
CD20+, Yr 3, Wk 24, n= 21231 (5 to 293)
CD20+, Yr 3, Wk 48, n= 20226 (5 to 500)
CD20+, Yr 4, Wk 24, n= 19627 (3 to 355)
CD20+, Yr 4, Wk 48, n= 18123 (5 to 238)
CD20+, Yr 5, Wk 24, n= 17222 (1 to 141)
CD20+, Yr 5, Wk 48, n= 16618.5 (5 to 248)
CD20+, Yr 6, Wk 24, n= 15921 (4 to 397)
CD20+, Yr 6, Wk 48, n= 11420 (4 to 113)
CD20+, Yr 7, Wk 24, n= 11120 (4 to 158)
CD20+, Yr 7, Wk 48, n= 8721 (5 to 120)
CD20+, Yr 8, Wk 24, n= 5417 (5 to 91)
CD20+, Yr 8, Wk 48, n= 2815.5 (5 to 57)
CD20+, Yr 9, Wk 24, n= 27.5 (7 to 8)
CD20+, Exit, n= 20722 (3 to 364)
CD19+/27BRIGHT/38BRIGHT SLE, Baseline, n= 26217 (0 to 600)
CD19+/27BRIGHT/38BRIGHT SLE, Yr 1, Wk 24, n= 25113 (0 to 452)
CD19+/27BRIGHT/38BRIGHT SLE, Yr 1, Wk 48, n= 24712 (0 to 177)
CD19+/27BRIGHT/38BRIGHT SLE, Yr 2, Wk 24, n= 24614 (0 to 204)
CD19+/27BRIGHT/38BRIGHT SLE, Yr 2, Wk 48, n= 23313 (0 to 345)
CD19+/27BRIGHT/38BRIGHT SLE, Yr 3, Wk 24, n= 21812 (0 to 216)
CD19+/27BRIGHT/38BRIGHT SLE, Yr 3, Wk 48, n= 21212 (0 to 331)
CD19+/27BRIGHT/38BRIGHT SLE, Yr 4, Wk 24, n= 21114 (0 to 407)
CD19+/27BRIGHT/38BRIGHT SLE, Yr 4, Wk 48, n= 19414 (0 to 442)
CD19+/27BRIGHT/38BRIGHT SLE, Yr 5, Wk 24, n= 18911 (0 to 414)
CD19+/27BRIGHT/38BRIGHT SLE, Yr 5, Wk 48, n= 18111 (0 to 591)
CD19+/27BRIGHT/38BRIGHT SLE, Yr 6, Wk 24, n= 17410.5 (0 to 443)
CD19+/27BRIGHT/38BRIGHT SLE, Yr 6, Wk 48, n= 13310 (0 to 248)
CD19+/27BRIGHT/38BRIGHT SLE, Yr 7, Wk 24, n= 1229 (0 to 381)
CD19+/27BRIGHT/38BRIGHT SLE, Yr 7, Wk 48, n= 978 (0 to 156)
CD19+/27BRIGHT/38BRIGHT SLE, Yr 8, Wk 24, n= 606.5 (0 to 755)
CD19+/27BRIGHT/38BRIGHT SLE, Yr 8, Wk 48, n= 295 (0 to 39)
CD19+/27BRIGHT/38BRIGHT SLE, Yr 9, Wk 24, n= 217.5 (6 to 29)
CD19+/27BRIGHT/38BRIGHT SLE, Exit, n= 2329 (0 to 555)
CD19+20-27hi+ SLPC, Baseline, n= 25816 (0 to 585)
CD19+20-27hi+ SLPC, Yr 1, Wk 24, n= 24713 (0 to 443)
CD19+20-27hi+ SLPC, Yr 1, Wk 48, n= 24411 (0 to 145)
CD19+20-27hi+ SLPC, Yr 2, Wk 24, n= 24413 (0 to 289)
CD19+20-27hi+ SLPC, Yr 2, Wk 48, n= 23313 (0 to 316)
CD19+20-27hi+ SLPC, Yr 3, Wk 24, n= 21812 (0 to 210)
CD19+20-27hi+ SLPC, Yr 3, Wk 48, n= 21112 (0 to 324)
CD19+20-27hi+ SLPC, Yr 4, Wk 24, n= 21013 (0 to 364)
CD19+20-27hi+ SLPC, Yr 4, Wk 48, n= 19312 (0 to 452)
CD19+20-27hi+ SLPC, Yr 5, Wk 24, n= 18810.5 (0 to 377)
CD19+20-27hi+ SLPC, Yr 5, Wk 48, n= 18110 (0 to 597)
CD19+20-27hi+ SLPC, Yr 6, Wk 24, n= 1749 (0 to 400)
CD19+20-27hi+ SLPC, Yr 6, Wk 48, n= 1338 (0 to 227)
CD19+20-27hi+ SLPC, Yr 7, Wk 24, n= 1229 (0 to 328)
CD19+20-27hi+ SLPC, Yr 7, Wk 48, n= 979 (0 to 156)
CD19+20-27hi+ SLPC, Yr 8, Wk 24, n= 609 (0 to 754)
CD19+20-27hi+ SLPC, Yr 8, Wk 48, n= 294 (0 to 42)
CD19+20-27hi+ SLPC, Yr 9, Wk 24, n= 216 (4 to 28)
CD19+20-27hi+ SLPC, Exit, n= 2339 (0 to 603)
CD20+/138+ plasmacytoid, Baseline, n= 26195 (0 to 4274)
CD20+/138+ plasmacytoid, Yr 1, Wk 24, n= 25164 (1 to 1613)
CD20+/138+ plasmacytoid, Yr 1, Wk 48, n= 24737 (2 to 962)
CD20+/138+ plasmacytoid, Yr 2, Wk 24, n= 24632.5 (0 to 221)
CD20+/138+ plasmacytoid, Yr 2, Wk 48, n= 23327 (1 to 249)
CD20+/138+ plasmacytoid, Yr 3, Wk 24, n= 21824 (0 to 322)
CD20+/138+ plasmacytoid, Yr 3, Wk 48, n= 21212 (0 to 220)
CD20+/138+ plasmacytoid, Yr 4, Wk 24, n= 2118 (0 to 128)
CD20+/138+ plasmacytoid, Yr 4, Wk 48, n= 1945 (0 to 246)
CD20+/138+ plasmacytoid, Yr 5, Wk 24, n= 1894 (0 to 136)
CD20+/138+ plasmacytoid, Yr 5, Wk 48, n= 1813 (0 to 102)
CD20+/138+ plasmacytoid, Yr 6, Wk 24, n= 1743 (0 to 38)
CD20+/138+ plasmacytoid, Yr 6, Wk 48, n= 1333 (0 to 25)
CD20+/138+ plasmacytoid, Yr 7, Wk 24, n= 1222 (0 to 70)
CD20+/138+ plasmacytoid, Yr 7, Wk 48, n= 972 (0 to 23)
CD20+/138+ plasmacytoid, Yr 8, Wk 24, n= 602 (0 to 18)
CD20+/138+ plasmacytoid, Yr 8, Wk 48, n= 291 (0 to 16)
CD20+/138+ plasmacytoid, Yr 9, Wk 24, n= 21 (0 to 2)
CD20+/138+ plasmacytoid, Exit, n= 2323 (0 to 231)
CD20+/27+Memory, Baseline, n= 26217 (0 to 177)
CD20+/27+Memory, Yr 1, Wk 24, n= 25130 (1 to 279)
CD20+/27+Memory, Yr 1, Wk 48, n= 24223 (0 to 275)
CD20+/27+Memory, Yr 2, Wk 24, n= 23817 (1 to 181)
CD20+/27+Memory, Yr 2, Wk 48, n= 22416 (1 to 686)
CD20+/27+Memory, Yr 3, Wk 24, n= 21213 (0 to 88)
CD20+/27+Memory, Yr 3, Wk 48, n= 20211 (1 to 342)
CD20+/27+Memory, Yr 4, Wk 24, n= 19610.5 (1 to 276)
CD20+/27+Memory, Yr 4, Wk 48, n= 1819 (1 to 196)
CD20+/27+Memory, Yr 5, Wk 24, n= 1728.5 (1 to 76)
CD20+/27+Memory, Yr 5, Wk 48, n= 1667 (1 to 166)
CD20+/27+Memory, Yr 6,Wk 24,n=1587 (1 to 73)
CD20+/27+Memory, Yr 6, Wk 48, n= 1146 (1 to 46)
CD20+/27+Memory, Yr 7, Wk 24, n= 1116 (1 to 91)
CD20+/27+Memory, Yr 7, Wk 48, n= 876 (1 to 81)
CD20+/27+Memory, Yr 8, Wk 24, n= 545 (1 to 34)
CD20+/27+Memory, Yr 8, Wk 48, n= 286 (1 to 32)
CD20+/27+Memory, Yr 9, Wk 24, n= 22 (1 to 3)
CD20+/27+Memory, Exit, n= 2078 (0 to 167)
CD20+/27-naive, Baseline, n= 26288 (1 to 717)
CD20+/27-naive, Yr 1, Wk 24, n= 25136 (1 to 371)
CD20+/27-naive, Yr 1, Wk 48, n= 24225 (1 to 209)
CD20+/27-naive, Yr 2, Wk 24, n= 23821 (2 to 176)
CD20+/27-naive, Yr 2, Wk 48, n= 22417 (1 to 826)
CD20+/27-naive, Yr 3, Wk 24, n= 21216 (1 to 243)
CD20+/27-naive, Yr 3, Wk 48, n= 20214 (1 to 163)
CD20+/27-naive, Yr 4, Wk 24, n= 19615 (2 to 140)
CD20+/27-naive, Yr 4, Wk 48, n= 18112 (1 to 152)
CD20+/27-naive, Yr 5, Wk 24, n= 17212.5 (0 to 127)
CD20+/27-naive, Yr 5, Wk 48, n= 16611 (2 to 176)
CD20+/27-naive, Yr 6, Wk 24, n= 15912 (0 to 67)
CD20+/27-naive, Yr 6, Wk 48, n= 11413 (1 to 68)
CD20+/27-naive, Yr 7, Wk 24, n= 11113 (1 to 69)
CD20+/27-naive, Yr 7, Wk 48, n= 8712 (2 to 59)
CD20+/27-naive, Yr 8, Wk 24, n= 5411.5 (2 to 62)
CD20+/27-naive, Yr 8, Wk 48, n= 2812 (2 to 54)
CD20+/27-naive, Yr 9, Wk 24, n= 25.5 (4 to 7)
CD20+/27-naive, Exit, n= 20713 (1 to 313)
CD20+/69+activated, Baseline, n= 257190 (11 to 2492)
CD20+/69+activated, Yr 1, Wk 24, n= 247131 (7 to 1503)
CD20+/69+activated, Yr 1, Wk 48, n= 24482 (1 to 561)
CD20+/69+activated, Yr 2, Wk 24, n= 24474 (0 to 916)
CD20+/69+activated, Yr 2, Wk 48, n= 23356 (0 to 472)
CD20+/69+activated, Yr 3, Wk 24, n= 21831 (0 to 242)
CD20+/69+activated, Yr 3, Wk 48, n= 21122 (0 to 233)
CD20+/69+activated, Yr 4, Wk 24, n= 21013 (0 to 687)
CD20+/69+activated, Yr 4, Wk 48, n= 1938 (0 to 288)
CD20+/69+activated, Yr 5, Wk 24, n= 1886 (0 to 147)
CD20+/69+activated, Yr 5, Wk 48, n= 1814 (0 to 61)
CD20+/69+activated, Yr 6, Wk 24, n= 1744 (0 to 40)
CD20+/69+activated, Yr 6, Wk 48, n= 1333 (0 to 56)
CD20+/69+activated, Yr 7, Wk 24, n= 1223 (0 to 43)
CD20+/69+activated, Yr 7, Wk 48, n= 972 (0 to 29)
CD20+/69+activated, Yr 8, Wk 24, n= 601.5 (0 to 21)
CD20+/69+activated, Yr 8, Wk 48, n= 291 (0 to 10)
CD20+/69+activated, Yr 9, Wk 24, n= 20.5 (0 to 1)
CD20+/69+activated, Exit, n= 2332 (0 to 457)
CD20-/138+plasma cells, Baseline, n= 26141 (1 to 870)
CD20-/138+plasma cells, Yr 1, Wk 24, n= 25131 (0 to 393)
CD20-/138+plasma cells, Yr 1, Wk 48, n= 24724 (0 to 255)
CD20-/138+plasma cells, Yr 2, Wk 24, n= 24623 (0 to 446)
CD20-/138+plasma cells, Yr 2, Wk 48, n= 23320 (0 to 1513)
CD20-/138+plasma cells, Yr 3, Wk 24, n= 21819 (0 to 312)
CD20-/138+plasma cells, Yr 3, Wk 48, n= 21216 (0 to 225)
CD20-/138+plasma cells, Yr 4, Wk 24, n= 21114 (0 to 337)
CD20-/138+plasma cells, Yr 4, Wk 48, n= 1947.5 (0 to 214)
CD20-/138+plasma cells, Yr 5, Wk 24, n= 1896 (0 to 135)
CD20-/138+plasma cells, Yr 5, Wk 48, n= 1816 (0 to 75)
CD20-/138+plasma cells, Yr 6, Wk 24, n= 1744 (0 to 50)
CD20-/138+plasma cells, Yr 6, Wk 48, n= 1334 (0 to 64)
CD20-/138+plasma cells, Yr 7, Wk 24, n= 1224.5 (0 to 84)
CD20-/138+plasma cells, Yr 7, Wk 48, n= 974 (0 to 47)
CD20-/138+plasma cells, Yr 8, Wk 24, n= 603 (0 to 75)
CD20-/138+plasma cells, Yr 8, Wk 48, n= 292 (0 to 28)
CD20-/138+plasma cells, Yr 9, Wk 24, n= 28 (2 to 14)
CD20-/138+plasma cells, Exit, n= 2325 (0 to 221)
Total CD19+ B-cells (CD19+), Baseline, n= 265114 (4 to 815)
Total CD19+ B-cells (CD19+), Yr 1, Wk 24, n= 25369 (4 to 437)
Total CD19+ B-cells (CD19+), Yr 1, Wk 48, n= 25449 (4 to 411)
Total CD19+ B-cells (CD19+), Yr 2, Wk 24, n= 24737 (4 to 281)
Total CD19+ B-cells (CD19+), Yr 2, Wk 48, n= 23434 (4 to 1559)
Total CD19+ B-cells (CD19+), Yr 3, Wk 24, n= 22030 (4 to 296)
Total CD19+ B-cells (CD19+), Yr 3, Wk 48, n= 21226 (4 to 510)
Total CD19+ B-cells (CD19+), Yr 4, Wk 24, n= 21125 (4 to 359)
Total CD19+ B-cells (CD19+), Yr 4, Wk 48, n= 19522 (4 to 245)
Total CD19+ B-cells (CD19+), Yr 5, Wk 24, n= 19019 (4 to 144)
Total CD19+ B-cells (CD19+), Yr 5, Wk 48, n= 18218 (4 to 301)
Total CD19+ B-cells (CD19+), Yr 6, Wk 24, n= 17519 (4 to 117)
Total CD19+ B-cells (CD19+), Yr 6, Wk 48, n= 13217.5 (4 to 114)
Total CD19+ B-cells (CD19+), Yr 7, Wk 24, n= 12218.5 (4 to 160)
Total CD19+ B-cells (CD19+), Yr 7, Wk 48, n= 9719 (4 to 121)
Total CD19+ B-cells (CD19+), Yr 8, Wk 24, n= 6016.5 (4 to 92)
Total CD19+ B-cells (CD19+), Yr 8, Wk 48, n= 2915 (4 to 58)
Total CD19+ B-cells (CD19+), Yr 9, Wk 24, n= 27.5 (7 to 8)
Total CD19+ B-cells (CD19+), Exit, n= 23420 (4 to 368)
SecondaryMedian Percent Change From Baseline in B Cell Levels at Indicated Time Points.

B-cell levels were assessed at Baseline (BL) (Day 0), Week (Wk) 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit. Median percent change from Baseline in absolute B cell subsets (CD20+), CD19+/27BRIGHT/38BRIGHT SLE subset, CD19+20-27hi+ short-lived plasma cells (SLPC), CD20+/138+ plasmacytoid, CD20+/27+ memory, CD20+/27- naïve, CD20+/69+activated, CD20-/138+ plasma cells, Total CD19+ B-cells (CD19+) levels are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Percent change from Baseline is calculated as: 100 x (\[Post-Dose Visit Value - Baseline\] / Baseline). Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

Time frame:
Up to Week 432
Reported as:
Median · Percentage change
Median Percent Change From Baseline in B Cell Levels at Indicated Time Points.
Percentage changeBelimumab 10 mg/kg IV
CD20+, Yr 1, Wk 24, n= 245-31.82 (-91.9 to 394.1)
CD20+, Yr 1, Wk 48, n= 237-51.61 (-94.7 to 216.7)
CD20+, Yr 2, Wk 24, n= 233-61.76 (-95.4 to 250)
CD20+, Yr 2, Wk 48, n= 218-66.21 (-96.3 to 1616.9)
CD20+, Yr 3, Wk 24, n= 206-69.68 (-96.2 to 250)
CD20+, Yr 3, Wk 48, n= 196-72.77 (-97.3 to 270.6)
CD20+, Yr 4, Wk 24, n= 191-75.16 (-96.8 to 82.4)
CD20+, Yr 4, Wk 48, n= 175-78.33 (-97.6 to 561.1)
CD20+, Yr 5, Wk 24, n= 166-80.26 (-97.6 to 156.3)
CD20+, Yr 5, Wk 48, n= 161-81.06 (-98.1 to 93.8)
CD20+, Yr 6, Wk 24, n= 154-81.87 (-98.1 to 2381.3)
CD20+, Yr 6, Wk 48, n= 109-82.94 (-96.7 to 102.9)
CD20+, Yr 7, Wk 24, n= 107-83.22 (-97.6 to 188.9)
CD20+, Yr 7, Wk 48, n= 82-80.96 (-97.3 to 172.2)
CD20+, Yr 8, Wk 24, n= 52-78.94 (-96.9 to 244.4)
CD20+, Yr 8, Wk 48, n= 27-85.29 (-95.5 to 105.9)
CD20+, Yr 9, Wk 24, n= 2-63.65 (-84.4 to -42.9)
CD20+, Exit, n= 203-80.6 (-98.2 to 225)
CD19+/27BRIGHT/38BRIGHT SLE, Yr 1, Wk 24, n= 243-16.13 (-100 to 4500)
CD19+/27BRIGHT/38BRIGHT SLE, Yr 1, Wk 48, n= 240-38.74 (-100 to 4800)
CD19+/27BRIGHT/38BRIGHT SLE, Yr 2, Wk 24, n= 239-25 (-100 to 2200)
CD19+/27BRIGHT/38BRIGHT SLE, Yr 2, Wk 48, n= 225-26.23 (-100 to 33100)
CD19+/27BRIGHT/38BRIGHT SLE, Yr 3, Wk 24, n= 210-33.97 (-100 to 6800)
CD19+/27BRIGHT/38BRIGHT SLE, Yr 3, Wk 48, n= 204-37.98 (-100 to 4900)
CD19+/27BRIGHT/38BRIGHT SLE, Yr 4, Wk 24, n= 204-19.52 (-100 to 2787.5)
CD19+/27BRIGHT/38BRIGHT SLE, Yr 4, Wk 48, n= 187-16.67 (-100 to 5500)
CD19+/27BRIGHT/38BRIGHT SLE, Yr 5, Wk 24, n= 182-33.33 (-100 to 4900)
CD19+/27BRIGHT/38BRIGHT SLE, Yr 5, Wk 48, n= 174-37.46 (-100 to 10000)
CD19+/27BRIGHT/38BRIGHT SLE, Yr 6, Wk 24, n= 167-44.44 (-100 to 11100)
CD19+/27BRIGHT/38BRIGHT SLE, Yr 6, Wk 48, n= 126-50 (-100 to 24700)
CD19+/27BRIGHT/38BRIGHT SLE, Yr 7, Wk 24, n= 117-50 (-100 to 29300)
CD19+/27BRIGHT/38BRIGHT SLE, Yr 7, Wk 48, n= 92-70.76 (-100 to 2100)
CD19+/27BRIGHT/38BRIGHT SLE, Yr 8, Wk 24, n= 57-71.43 (-100 to 1787.5)
CD19+/27BRIGHT/38BRIGHT SLE, Yr 8, Wk 48, n= 28-85 (-100 to 100)
CD19+/27BRIGHT/38BRIGHT SLE, Yr 9, Wk 24, n= 2210.98 (-78 to 500)
CD19+/27BRIGHT/38BRIGHT SLE, Exit, n= 226-50 (-100 to 6100)
CD19+20-27hi+ SLPC, Yr 1, Wk 24, n= 238-32.29 (-100 to 4330)
CD19+20-27hi+ SLPC, Yr 1, Wk 48, n= 235-40 (-100 to 1400)
CD19+20-27hi+ SLPC, Yr 2, Wk 24, n= 234-27.05 (-100 to 2000)
CD19+20-27hi+ SLPC, Yr 2, Wk 48, n= 221-30 (-100 to 4385.7)
CD19+20-27hi+ SLPC, Yr 3, Wk 24, n= 207-37.5 (-100 to 1300)
CD19+20-27hi+ SLPC, Yr 3, Wk 48, n= 199-40.54 (-100 to 6600)
CD19+20-27hi+ SLPC, Yr 4, Wk 24, n= 199-29.41 (-100 to 1900)
CD19+20-27hi+ SLPC, Yr 4, Wk 48, n= 184-29.29 (-100 to 1250)
CD19+20-27hi+ SLPC, Yr 5, Wk 24, n= 178-44.6 (-100 to 1400)
CD19+20-27hi+ SLPC, Yr 5, Wk 48, n= 171-45.65 (-100 to 1328.6)
CD19+20-27hi+ SLPC, Yr 6, Wk 24, n= 165-62.5 (-100 to 3400)
CD19+20-27hi+ SLPC, Yr 6, Wk 48, n= 123-62.5 (-100 to 3400)
CD19+20-27hi+ SLPC, Yr 7, Wk 24, n= 114-47.5 (-100 to 4128.6)
CD19+20-27hi+ SLPC, Yr 7, Wk 48, n= 89-58.33 (-100 to 2900)
CD19+20-27hi+ SLPC, Yr 8, Wk 24, n= 55-62.07 (-100 to 1884.2)
CD19+20-27hi+ SLPC, Yr 8, Wk 48, n= 27-84.62 (-100 to 10.5)
CD19+20-27hi+ SLPC, Yr 9, Wk 24, n= 1-79.4 (-79.4 to -79.4)
CD19+20-27hi+ SLPC, Exit, n= 224-51.42 (-100 to 2000)
CD20+/138+ plasmacytoid, Yr 1, Wk 24, n= 243-32.49 (-97.4 to 6352)
CD20+/138+ plasmacytoid, Yr 1, Wk 48, n= 240-61.11 (-99 to 923.4)
CD20+/138+ plasmacytoid, Yr 2, Wk 24, n= 239-66 (-100 to 2233.3)
CD20+/138+ plasmacytoid, Yr 2, Wk 48, n= 225-70.64 (-99.2 to 422.2)
CD20+/138+ plasmacytoid, Yr 3, Wk 24, n= 211-78.57 (-100 to 644.4)
CD20+/138+ plasmacytoid, Yr 3, Wk 48, n= 204-88.89 (-100 to 863.6)
CD20+/138+ plasmacytoid, Yr 4, Wk 24, n= 204-93.14 (-100 to 156)
CD20+/138+ plasmacytoid, Yr 4, Wk 48, n= 186-94.17 (-100 to 35)
CD20+/138+ plasmacytoid, Yr 5, Wk 24, n= 181-96.25 (-100 to 33.3)
CD20+/138+ plasmacytoid, Yr 5, Wk 48, n= 174-96.75 (-100 to -21.2)
CD20+/138+ plasmacytoid, Yr 6, Wk 24, n= 167-96.53 (-100 to -9.1)
CD20+/138+ plasmacytoid, Yr 6, Wk 48, n= 126-97.96 (-100 to -36.4)
CD20+/138+ plasmacytoid, Yr 7, Wk 24, n= 117-98 (-100 to -33.3)
CD20+/138+ plasmacytoid, Yr 7, Wk 48, n= 91-98.46 (-100 to -40)
CD20+/138+ plasmacytoid, Yr 8, Wk 24, n= 57-98.64 (-100 to -70)
CD20+/138+ plasmacytoid, Yr 8, Wk 48, n= 28-98.68 (-100 to -92.9)
CD20+/138+ plasmacytoid, Yr 9, Wk 24, n= 2-96.15 (-100 to -92.3)
CD20+/138+ plasmacytoid, Exit, n= 225-96.83 (-100 to 610.7)
CD20+/27+Memory, Yr 1, Wk 24, n= 24487.65 (-97.1 to 1420)
CD20+/27+Memory, Yr 1, Wk 48, n= 23742.86 (-100 to 800)
CD20+/27+Memory, Yr 2, Wk 24, n= 23311.11 (-88.9 to 700)
CD20+/27+Memory, Yr 2, Wk 48, n= 217-7.69 (-84.6 to 5616.7)
CD20+/27+Memory, Yr 3, Wk 24, n= 205-23.26 (-100 to 900)
CD20+/27+Memory, Yr 3, Wk 48, n= 196-35.29 (-97.1 to 3000)
CD20+/27+Memory, Yr 4, Wk 24, n= 191-40 (-92.6 to 1400)
CD20+/27+Memory, Yr 4, Wk 48, n= 175-50 (-92.3 to 3166.7)
CD20+/27+Memory, Yr 5, Wk 24, n= 166-50 (-97.7 to 500)
CD20+/27+Memory, Yr 5, Wk 48, n= 160-58.87 (-96 to 800)
CD20+/27+Memory, Yr 6, Wk 24, n= 153-57.89 (-96.2 to 533.3)
CD20+/27+Memory, Yr 6, Wk 48, n= 108-63.4 (-92.9 to 400)
CD20+/27+Memory, Yr 7, Wk 24, n= 106-67.18 (-96.2 to 500)
CD20+/27+Memory, Yr 7, Wk 48, n= 81-71.43 (-92.3 to 400)
CD20+/27+Memory, Yr 8, Wk 24, n= 52-67.03 (-96 to 200)
CD20+/27+Memory, Yr 8, Wk 48, n= 27-64.71 (-88.8 to 600)
CD20+/27+Memory, Yr 9, Wk 24, n= 2-75.96 (-76.9 to -75)
CD20+/27+Memory, Exit, n= 202-61.41 (-100 to 1000)
CD20+/27-naive, Yr 1, Wk 24, n= 245-55.56 (-95.1 to 337.5)
CD20+/27-naive, Yr 1, Wk 48, n= 237-69.7 (-96.7 to 200)
CD20+/27-naive, Yr 2, Wk 24, n= 233-77.27 (-97.6 to 150)
CD20+/27-naive, Yr 2, Wk 48, n= 218-79.5 (-98.6 to 959)
CD20+/27-naive, Yr 3, Wk 24, n= 206-80.11 (-98.5 to 100)
CD20+/27-naive, Yr 3, Wk 48, n= 196-84.41 (-98.5 to 500)
CD20+/27-naive, Yr 4, Wk 24, n= 191-81.93 (-98.8 to 100)
CD20+/27-naive, Yr 4, Wk 48, n= 175-84.21 (-98.8 to 100)
CD20+/27-naive, Yr 5, Wk 24, n= 166-86.09 (-100 to 66.7)
CD20+/27-naive, Yr 5, Wk 48, n= 161-87.5 (-99.2 to 57.7)
CD20+/27-naive, Yr 6, Wk 24, n= 154-86.88 (-100 to 233.3)
CD20+/27-naive, Yr 6, Wk 48, n= 109-86.93 (-97.7 to 100)
CD20+/27-naive, Yr 7, Wk 24, n= 107-87.39 (-98.4 to 300)
CD20+/27-naive, Yr 7, Wk 48, n= 82-84.78 (-98 to 300)
CD20+/27-naive, Yr 8, Wk 24, n= 52-83.7 (-97.9 to 510)
CD20+/27-naive, Yr 8, Wk 48, n= 27-88.15 (-96.5 to 86.7)
CD20+/27-naive, Yr 9, Wk 24, n= 2-61.93 (-87.5 to -36.4)
CD20+/27-naive, Exit, n= 203-86.42 (-99 to 433.3)
CD20+/69+activated, Yr 1, Wk 24, n= 240-33.35 (-98.5 to 3000)
CD20+/69+activated, Yr 1, Wk 48, n= 238-56.33 (-99.7 to 1331.6)
CD20+/69+activated, Yr 2, Wk 24, n= 236-65.21 (-100 to 580)
CD20+/69+activated, Yr 2, Wk 48, n= 223-72.31 (-100 to 502.9)
CD20+/69+activated, Yr 3, Wk 24, n= 208-83.71 (-100 to 306.9)
CD20+/69+activated, Yr 3, Wk 48, n= 202-89.28 (-100 to 325.7)
CD20+/69+activated, Yr 4, Wk 24, n= 201-93.14 (-100 to 89.3)
CD20+/69+activated, Yr 4, Wk 48, n= 185-94.85 (-100 to 263.6)
CD20+/69+activated, Yr 5, Wk 24, n= 180-96.99 (-100 to 13.4)
CD20+/69+activated, Yr 5, Wk 48, n= 172-98.04 (-100 to 14.3)
CD20+/69+activated, Yr 6, Wk 24, n= 165-98.04 (-100 to -16.7)
CD20+/69+activated, Yr 6, Wk 48, n= 125-98.76 (-100 to 20)
CD20+/69+activated, Yr 7, Wk 24, n= 116-98.85 (-100 to -24.1)
CD20+/69+activated, Yr 7, Wk 48, n=89-99.22 (-100 to -76)
CD20+/69+activated, Yr 8, Wk 24, n= 56-99.33 (-100 to -83.7)
CD20+/69+activated, Yr 8, Wk 48, n= 28-99.71 (-100 to -95.8)
CD20+/69+activated, Yr 9, Wk 24, n= 2-97.92 (-100 to -95.8)
CD20+/69+activated, Exit, n= 226-98.99 (-100 to 453.1)
CD20-/138+plasma cells, Yr 1, Wk 24, n= 244-37.2 (-100 to 3400)
CD20-/138+plasma cells, Yr 1, Wk 48, n= 241-50 (-100 to 4700)
CD20-/138+plasma cells, Yr 2, Wk 24, n= 240-47.83 (-100 to 1200)
CD20-/138+plasma cells, Yr 2, Wk 48, n= 226-53.92 (-100 to 5500)
CD20-/138+plasma cells, Yr 3, Wk 24, n= 212-64.82 (-100 to 1000)
CD20-/138+plasma cells, Yr 3, Wk 48, n= 205-71.43 (-100 to 2566.7)
CD20-/138+plasma cells, Yr 4, Wk 24, n= 205-73.76 (-100 to 910)
CD20-/138+plasma cells, Yr 4, Wk 48, n= 187-81.58 (-100 to 586.4)
CD20-/138+plasma cells, Yr 5, Wk 24, n= 182-86.46 (-100 to 133.3)
CD20-/138+plasma cells, Yr 5, Wk 48, n= 175-88.89 (-100 to 300)
CD20-/138+plasma cells, Yr 6, Wk 24, n= 168-91.3 (-100 to 900)
CD20-/138+plasma cells, Yr 6, Wk 48, n= 127-90.91 (-100 to 2100)
CD20-/138+plasma cells, Yr 7, Wk 24, n= 118-92.31 (-100 to 1700)
CD20-/138+plasma cells, Yr 7, Wk 48, n= 92-93.83 (-100 to 200)
CD20-/138+plasma cells, Yr 8, Wk 24, n= 57-93.39 (-100 to -11.1)
CD20-/138+plasma cells, Yr 8, Wk 48, n= 28-97.56 (-100 to -75)
CD20-/138+plasma cells, Yr 9, Wk 24, n= 2-80.78 (-90.1 to -71.4)
CD20-/138+plasma cells, Exit, n= 226-88.58 (-100 to 1600)
Total CD19+ B-cells (CD19+), Yr 1, Wk 24, n= 250-32.56 (-91.7 to 400)
Total CD19+ B-cells (CD19+), Yr 1, Wk 48, n= 251-51.61 (-94.6 to 214.3)
Total CD19+ B-cells (CD19+), Yr 2, Wk 24, n= 244-61.71 (-95.5 to 244.4)
Total CD19+ B-cells (CD19+), Yr 2, Wk 48, n= 231-66.67 (-96 to 1576.3)
Total CD19+ B-cells (CD19+), Yr 3, Wk 24, n= 217-70.21 (-96.3 to 153.3)
Total CD19+ B-cells (CD19+), Yr 3, Wk 48, n= 209-74.24 (-97.3 to 276.5)
Total CD19+ B-cells (CD19+), Yr 4, Wk 24, n= 209-75.61 (-97.8 to 82.4)
Total CD19+ B-cells (CD19+), Yr 4, Wk 48, n= 192-78.54 (-97.8 to 528.2)
Total CD19+ B-cells (CD19+), Yr 5, Wk 24, n= 187-80.56 (-97.8 to 141.2)
Total CD19+ B-cells (CD19+), Yr 5, Wk 48, n= 179-81.14 (-98.1 to 100)
Total CD19+ B-cells (CD19+), Yr 6, Wk 24, n= 172-81.85 (-98.1 to 75)
Total CD19+ B-cells (CD19+), Yr 6, Wk 48, n= 130-82.34 (-98.5 to 79.5)
Total CD19+ B-cells (CD19+), Yr 7, Wk 24, n= 120-82.73 (-97.6 to 125)
Total CD19+ B-cells (CD19+), Yr 7, Wk 48, n= 95-80.95 (-97.8 to 172.2)
Total CD19+ B-cells (CD19+), Yr 8, Wk 24, n= 59-79.87 (-96.9 to 250)
Total CD19+ B-cells (CD19+), Yr 8, Wk 48, n= 28-84.79 (-95.6 to 94.4)
Total CD19+ B-cells (CD19+), Yr 9, Wk 24, n= 2-66.04 (-85.4 to -46.7)
Total CD19+ B-cells (CD19+), Exit, n= 232-80.81 (-98.2 to 178.6)
SecondaryPercentage of Participants With Worsening in SLICC/ACR Damage Index at Indicated Time Points

Systemic Lupus International Collaborative Clinics/American College of Rheumatology (SLICC/ACR) Damage Index is a tool used to assess non-reversible organ damage in SLE patients. Damage Index is used to assess 12 systems by 41 items. Score is given as 1 or sometimes 2, if occur more than once, so that that the maximum possible score is 47. Higher damage index scores early in disease are associated with a poor prognosis and with increased mortality. Damage index was assessed at BL (Day 0), Week 48 in first year, at Week 48 in subsequent years up to 8 years. Percentage of participants with worsening in damage index (change \>0) are summarized. The BL is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points were analyzed ( n=X).

Time frame:
Up to Week 384
Reported as:
Number · Percentage of Participants
Percentage of Participants With Worsening in SLICC/ACR Damage Index at Indicated Time Points
Percentage of ParticipantsBelimumab 10 mg/kg IV
Year 1, Week 48, n=2635.7
Year 2, Week 48, n=25612.1
Year 3, Week 48, n=23918
Year 4, Week 48, n=21220.8
Year 5, Week 48, n=19522.6
Year 6, Week 48, n=18725.1
Year 7, Week 48, n=12630.2
Year 8, Week 48, n=6529.2
SecondaryChange From Baseline in SF-36 Healthy Survey Overall Component Scores at Indicated Time Point

The SF-36v2 is a participant-reported short form survey to measure functional health and well-being. There are 36 items grouped into eight health domains: Vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning and mental health. SF-36v2 gives a score (0-100) for each of these domains as well as summary score for the physical component score (PCS) and mental component score (MCS) based on the responses by participants. The lower the score the more disability and the higher the score the less disability. The BL is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from BL was calculated as the individual post-BL value minus the BL value. Only those participants available at the specified time points were analyzed ( n=X).

Time frame:
Up to Week 384
Reported as:
Mean · Score on a scale
Change From Baseline in SF-36 Healthy Survey Overall Component Scores at Indicated Time Point
Score on a scaleBelimumab 10 mg/kg IV
MCS, Year 1, Week 48, n= 2592.47 ± 10.113
MCS, Year 2, Week 48, n= 2552.99 ± 10.428
MCS, Year 3, Week 48, n= 2362.54 ± 10.399
MCS, Year 4, Week 48, n= 2122.52 ± 11.099
MCS, Year 5, Week 48, n= 1932.22 ± 11.22
MCS, Year 6, Week 48, n= 1852.71 ± 11.274
MCS, Year 7, Week 48, n= 1263.19 ± 11.269
MCS, Year 8, Week 48, n= 653.91 ± 11.066
PCS, Year 1, Week 48, n= 2593.41 ± 8.603
PCS, Year 2, Week 48, n= 2554.64 ± 8.3
PCS, Year 3, Week 48, n= 2365.93 ± 8.51
PCS, Year 4, Week 48, n= 2125.01 ± 8.752
PCS, Year 5, Week 48, n= 1936.12 ± 9.314
PCS, Year 6, Week 48, n= 1854.79 ± 9.406
PCS, Year 7, Week 48, n= 1267.7 ± 9.887
PCS, Year 8, Week 48, n= 656.73 ± 10.107
SecondaryChange From Baseline in SF-36 Healthy Survey Overall Component Scores at Indicated Timepoints

The SF-36v2 is a participant-reported survey to measure functional health and well-being. There are 36 items grouped into eight health domains: Vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning and mental health. SF-36v2 gives a score (0-100) for each of these domains as well as summary score for the physical component score (PCS) and mental component score (MCS) based on the responses by participants. The lower the score the more disability and the higher the score the less disability. The BL is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from BL was calculated as the individual post-BL value minus the BL value. Only those participants available at the specified time points were analyzed ( n=X).

Time frame:
Up to Week 384
Reported as:
Mean · Score on a scale
Change From Baseline in SF-36 Healthy Survey Overall Component Scores at Indicated Timepoints
Score on a scaleBelimumab 10 mg/kg IV
Bodily pain, Year 1 , Week 48, n= 2619.7 ± 23.36
Bodily pain, Year 2 , Week 48, n= 2559.2 ± 24.389
Bodily pain, Year 3 , Week 48, n= 23610.97 ± 23.409
Bodily pain, Year 4 , Week 48, n= 2128.33 ± 24.181
Bodily pain, Year 5 , Week 48, n= 19310.88 ± 24.549
Bodily pain, Year 6 , Week 48, n= 1858.82 ± 23.636
Bodily pain, Year 7 , Week 48, n= 12614.48 ± 24.969
Bodily pain, Year 8 , Week 48, n= 6511.94 ± 22.93
General health, Year 1 , Week 48, n= 2605.66 ± 14.693
General health, Year 2 , Week 48, n= 2556.14 ± 15.156
General health, Year 3 , Week 48, n= 2368.84 ± 15.929
General health, Year 4 , Week 48, n= 2127.29 ± 16.069
General health, Year 5 , Week 48, n= 1939.19 ± 17.742
General health, Year 6 , Week 48, n= 1857.24 ± 18.187
General health, Year 7 , Week 48, n= 1268.71 ± 18.693
General health, Year 8 , Week 48, n= 658.18 ± 19.994
Mental health, Year 1 , Week 48, n= 2604 ± 17.71
Mental health, Year 2 , Week 48, n= 2553.62 ± 17.46
Mental health, Year 3 , Week 48, n= 2362.34 ± 17.817
Mental health, Year 4 , Week 48, n= 2122.33 ± 20.172
Mental health, Year 5 , Week 48, n= 1931.78 ± 20.662
Mental health, Year 6 , Week 48, n= 1853.6 ± 19.968
Mental health, Year 7 , Week 48, n= 1264.39 ± 19.811
Mental health, Year 8 , Week 48, n= 656.08 ± 18.551
Physical functioning, Year 1 , Week 48, n= 2606.34 ± 21.498
Physical functioning, Year 2 , Week 48, n= 2556.25 ± 21.185
Physical functioning, Year 3 , Week 48, n= 2367.85 ± 21.994
Physical functioning, Year 4 , Week 48, n= 2126.38 ± 22.112
Physical functioning, Year 5 , Week 48, n= 1937.62 ± 24.486
Physical functioning, Year 6 , Week 48, n= 1856.72 ± 24.81
Physical functioning, Year 7 , Week 48, n= 12611.25 ± 26.422
Physical functioning, Year 8 , Week 48, n= 6511.83 ± 27.065
Role emotional, Year 1 , Week 48, n= 2614.96 ± 25.714
Role emotional, Year 2 , Week 48, n= 2544.74 ± 27.92
Role emotional, Year 3 , Week 48, n= 2363.73 ± 28.258
Role emotional, Year 4 , Week 48, n= 2123.32 ± 28.237
Role emotional, Year 5 , Week 48, n= 1933.61 ± 28.774
Role emotional, Year 6 , Week 48, n= 1853.13 ± 31.614
Role emotional, Year 7 , Week 48, n= 1263.27 ± 30.385
Role emotional, Year 8 , Week 48, n=657.18 ± 33.91
Role physical, Year 1 , Week 48, n= 2608.91 ± 26.393
Role physical, Year 2 , Week 48, n= 2538 ± 27.106
Role physical, Year 3 , Week 48, n= 23610.05 ± 26.525
Role physical, Year 4 , Week 48, n= 2128.27 ± 28.998
Role physical, Year 5 , Week 48, n= 19310.86 ± 29.839
Role physical, Year 6 , Week 48, n= 1856.91 ± 30.995
Role physical, Year 7 , Week 48, n= 12613.53 ± 31.347
Role physical, Year 8 , Week 48, n= 6511.51 ± 34.385
Social functioning, Year 1 , Week 48, n= 2617.61 ± 26.901
Social functioning, Year 2 , Week 48, n= 2557.21 ± 27.218
Social functioning, Year 3 , Week 48, n= 2369.59 ± 27.989
Social functioning, Year 4 , Week 48, n= 2126.9 ± 28.598
Social functioning, Year 5 , Week 48, n= 1938.16 ± 30.079
Social functioning, Year 6 , Week 48, n= 1856.96 ± 28.695
Social functioning, Year 7 , Week 48, n= 12610.32 ± 31.784
Social functioning, Year 8 , Week 48, n= 659.81 ± 32.135
Vitality, Year 1 , Week 48, n= 2608.87 ± 21.449
Vitality, Year 2 , Week 48, n= 2557.13 ± 22.287
Vitality, Year 3 , Week 48, n= 2368.17 ± 20.742
Vitality, Year 4 , Week 48, n= 2128.04 ± 21.742
Vitality, Year 5 , Week 48, n= 1938.23 ± 24.937
Vitality, Year 6 , Week 48, n= 1856.93 ± 23.023
Vitality, Year 7 , Week 48, n= 12611.69 ± 22.709
Vitality, Year 8 , Week 48, n= 656.47 ± 22.033
SecondaryChange From Baseline in FACIT-Fatigue Scale Total Score at Indicated Time Point

The FACIT-F scale measures the severity and impact of fatigue on functioning and health related quality of life experienced in the past 7 days. FACIT-Fatigue scale total score was assessed at BL (Day 0), Wk 48 in first year, at Wk 48 in subsequent Yrs up to 8 Yrs.The level of fatigue is measured by 13 questions assessed on a four-point scale (0=not at all fatigued; 1=a little bit fatigued; 2=somewhat fatigued; 3=quite a bit fatigued; 4=very much fatigued; possible total score of 0 to 52). Change from BL in FACIT-Fatigue scale total score are summarized. The BL is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from BL was calculated as the individual post-BL value minus the BL value. A negative change from BL represents a worsening condition. Only those participants available at the specified time points were analyzed ( n=X).

Time frame:
Up to Week 384
Reported as:
Mean · Score on a scale
Change From Baseline in FACIT-Fatigue Scale Total Score at Indicated Time Point
Score on a scaleBelimumab 10 mg/kg IV
Year 1, Week 48, n= 2604.91 ± 10.785
Year 2, Week 48, n= 2524.82 ± 11.414
Year 3, Week 48, n= 2354.85 ± 11.614
Year 4, Week 48, n= 2104.14 ± 11.269
Year 5, Week 48, n= 1934.81 ± 11.962
Year 6, Week 48, n= 1843.7 ± 11.787
Year 7, Week 48, n= 1265.74 ± 11.644
Year 8, Week 48, n= 654.28 ± 10.949
SecondaryPercentage of Participants With Improvement in FACIT-Fatigue Scale Score Exceeding the MCID at Indicated Time Points

The FACIT-F scale measures the severity and impact of fatigue on functioning and health related quality of life experienced in the past 7 days. FACIT-Fatigue scale total score was assessed at BL (Day 0), Week 48 in first year, at Week 48 in subsequent years up to 8 years. The level of fatigue is measured by 13 questions assessed on a four-point scale (0=not at all fatigued; 1=a little bit fatigued; 2=somewhat fatigued; 3=quite a bit fatigued; 4=very much fatigued; possible total score of 0 to 52). Percentage of participants with improvement in FACIT-Fatigue scale score exceeding the minimum clinically important difference (MCID) (\>=4 points) are summarized. Only those participants available at the specified time points were analyzed ( n=X).

Time frame:
Up to Week 384
Reported as:
Number · Percentage of Participants
Percentage of Participants With Improvement in FACIT-Fatigue Scale Score Exceeding the MCID at Indicated Time Points
Percentage of ParticipantsBelimumab 10 mg/kg IV
Year 1, Week 4850.4
Year 2, Week 4845.9
Year 3, Week 4844.4
Year 4, Week 4836.2
Year 5, Week 4840.3
Year 6, Week 4833.2
Year 7, Week 4826.1
Year 8, Week 4813.1

Adverse events

Collected over On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from Day 1 until follow-up (up to Week 440).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Belimumab 10 mg/kg IV—112/268 (41.8%)266/268 (99.3%)
Most frequent serious events
Showing 10 of 212
Most frequent serious events
EventBelimumab 10 mg/kg IV
Any eventInfections and infestations44/268
Any eventMusculoskeletal and connective tissue disorders22/268
Any eventGeneral disorders20/268
Any eventGastrointestinal disorders19/268
Any eventInjury, poisoning and procedural complications15/268
Any eventNervous system disorders15/268
Any eventNeoplasms benign, malignant and unspecified (incl cysts and polyps)13/268
Non-cardiac chest painGeneral disorders12/268
Any eventRespiratory, thoracic and mediastinal disorders11/268
Any eventVascular disorders10/268
Most frequent other events
Showing 10 of 103
Most frequent other events
EventBelimumab 10 mg/kg IV
Any eventInfections and infestations243/268
Any eventMusculoskeletal and connective tissue disorders217/268
Any eventGastrointestinal disorders191/268
Any eventSkin and subcutaneous tissue disorders163/268
Any eventNervous system disorders162/268
Any eventInjury, poisoning and procedural complications155/268
Any eventRespiratory, thoracic and mediastinal disorders154/268
Any eventGeneral disorders151/268
Any eventPsychiatric disorders107/268
ArthralgiaMusculoskeletal and connective tissue disorders106/268

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Belimumab 10 mg/kg IV
Mean42.8 ± 11.33
Sex: Female, Male
Sex: Female, Male(Participants)Belimumab 10 mg/kg IV
Female250
Male18
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Belimumab 10 mg/kg IV
Black or African American/African Heritage57
American Indian or Alaska Native8
Asian: Central Asian Heritage0
Asian: East Asian Heritage2
Asian: Japanese Heritage3
Asian: South Asian Heritage1
Asian: Southeast Asian Heritage7
Native Hawaiian or Other Pacific Islander0
White: Middle East/North African Heritage3
White: White/Caucasian/European Heritage183
Mixed Race4
08

Study locations

51 sites
  • GSK Investigational Site
    Birmingham, Alabama 35249, United States
  • GSK Investigational Site
    Phoenix, Arizona 85032, United States
  • GSK Investigational Site
    Tucson, Arizona 85724, United States
  • GSK Investigational Site
    Long Beach, California 90806, United States
  • GSK Investigational Site
    Los Angeles, California 90033, United States
  • GSK Investigational Site
    Los Angeles, California 90048, United States
  • GSK Investigational Site
    Upland, California 91786, United States
  • GSK Investigational Site
    Washington, District of Columbia 20010, United States
  • GSK Investigational Site
    Aventura, Florida 33180, United States
  • GSK Investigational Site
    Orlando, Florida 32806, United States
  • GSK Investigational Site
    Tampa, Florida 33614, United States
  • GSK Investigational Site
    Atlanta, Georgia 30303, United States
  • GSK Investigational Site
    Chicago, Illinois 60612, United States
  • GSK Investigational Site
    Chicago, Illinois 60637, United States
  • GSK Investigational Site
    Munster, Indiana 46321, United States
  • GSK Investigational Site
    Kansas City, Kansas 66160, United States
  • GSK Investigational Site
    Louisville, Kentucky 40202, United States
  • GSK Investigational Site
    Baton Rouge, Louisiana 70809, United States
  • GSK Investigational Site
    Baltimore, Maryland 21205, United States
  • GSK Investigational Site
    Cumberland, Maryland 21502, United States
  • GSK Investigational Site
    Hagerstown, Maryland 21740, United States
  • GSK Investigational Site
    Ann Arbor, Michigan 48109-5542, United States
  • GSK Investigational Site
    Lansing, Michigan 48910, United States
  • GSK Investigational Site
    Bronx, New York 10461, United States
  • GSK Investigational Site
    Brooklyn, New York 11203, United States
  • GSK Investigational Site
    Great Neck, New York 11021, United States
  • GSK Investigational Site
    Manhasset, New York 11030, United States
  • GSK Investigational Site
    New York, New York 10016, United States
  • GSK Investigational Site
    Rochester, New York 14618, United States
  • GSK Investigational Site
    Smithtown, New York 11787, United States
  • GSK Investigational Site
    Chapel Hill, North Carolina 27599, United States
  • GSK Investigational Site
    Greenville, North Carolina 27834, United States
  • GSK Investigational Site
    Winston-Salem, North Carolina 27157, United States
  • GSK Investigational Site
    Columbus, Ohio 43203, United States
  • GSK Investigational Site
    Dayton, Ohio 45417, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 74104, United States
  • GSK Investigational Site
    Tulsa, Oklahoma 74104, United States
  • GSK Investigational Site
    Bethlehem, Pennsylvania 18015, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15217, United States
  • GSK Investigational Site
    Charleston, South Carolina 29406, United States
  • GSK Investigational Site
    Charleston, South Carolina 29425, United States
  • GSK Investigational Site
    Greenville, South Carolina 29601, United States
  • GSK Investigational Site
    Austin, Texas 78705, United States
  • GSK Investigational Site
    Houston, Texas 77004, United States
  • GSK Investigational Site
    Houston, Texas 77034, United States
  • GSK Investigational Site
    Houston, Texas 77074, United States
  • GSK Investigational Site
    San Antonio, Texas 78232, United States
  • GSK Investigational Site
    Sugar Land, Texas 77479, United States
  • GSK Investigational Site
    Arlington, Virginia 22205-3606, United States
  • GSK Investigational Site
    Seattle, Washington 98133, United States
  • GSK Investigational Site
    Onalaska, Wisconsin 54650, United States
09

References and documents

Publications

  • Strand V, Berry P, Lin X, Asukai Y, Punwaney R, Ramachandran S. Long-Term Impact of Belimumab on Health-Related Quality of Life and Fatigue in Patients With Systemic Lupus Erythematosus: Six Years of Treatment. Arthritis Care Res (Hoboken). 2019 Jun;71(6):829-838. doi: 10.1002/acr.23788. Epub 2019 Apr 29. PubMed 30320964 ↗
  • Furie RA, Wallace DJ, Aranow C, Fettiplace J, Wilson B, Mistry P, Roth DA, Gordon D. Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States. Arthritis Rheumatol. 2018 Jun;70(6):868-877. doi: 10.1002/art.40439. Epub 2018 Apr 25. PubMed 29409143 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Mar 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2016, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2008
First posted
Jul 30, 2008
Start
Aug 2008
Primary completionActual
Mar 2015
CompletionActual
Mar 2015
Results first posted
Mar 28, 2016
Last update
Mar 28, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00724867
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 30, 2008
Start date
Aug 2008
Primary completion
Mar 2015
Completion
Mar 2015
Results posted
Mar 28, 2016
Last update
Mar 28, 2016

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belimumab

Start the discussion